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Summary of Thesis 
 
Background 
Papillary Thyroid Cancer (PTC) is a common endocrine cancer which metastases to 
the cervical lymph nodes (LN). The frequency of metastasis is poorly defined. The 
imaging modalities commonly employed to detect these metastases have 
limitations. The aim of this study was to define the extent of cervical LN metastases, 
the role of imaging in their detection and to determine long term outcomes.  
Design and Methods 
The study was designed in two parts. 
A. Systematic reviews of incidence of cervical LN metastases in PTC and the use of 
imaging modalities in detection of these LN. 
B. Retrospective Cohort Study of PTC patients: Data from three centres in London 
over the last 9 years was collected and analysed.  
Results 
I. Systematic reviews 
A. Central LN Dissection (LND): 21 studies provided data for 4188 patients. Among 
patients who underwent prophylactic central LND (pCLND), 772 had positive central 
LN (44.8 %).   
B. Lateral LND: 19 studies provided data for 5587 patients. Out of 2048 patients who 
underwent pLLND, 1177 were found to have positive lateral LNs (57.5%).  
C. Imaging of metastatic cervical LN 
Ultrasound: The sensitivity to detect central and lateral cervical LN was 38.4% and 
27.2% respectively. 
Computerised Tomography: The sensitivity to detect central LN was 67%. For lateral 
LN none of the studies calculated the sensitivity accurately. 
II. Results from the Cohort Study 
44 patients were included in the analyses. 53.8% had positive LN when pLLND 
dissection was performed.  Recurrence free survival between the two cohorts was 





Prophylactic LND yielded metastatic central and lateral LN in about half of all 
patients with PTC.  Imaging modalities currently utilised for detection of metastatic 
central and lateral cervical LN have low sensitivities. In our cohort of patients, 
prophylactic lateral lymph node dissection did not show any significant difference in 
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1.1 Thyroid Nodule 
Introduction 
The most common presentation of thyroid cancer is a newly diagnosed thyroid 
nodule or increase in size of an existing nodule (Perros, Boelaert et al. 2014). 
Thyroid nodules are common clinical findings with a prevalence of 3-7% on palpation 
(Tunbridge, Evered et al. 1977). With increased use of high resolution ultrasound 
scans, the incidence is reported to be much higher in the region of 20-76% (Ezzat, 
Sarti et al. 1994). Clear majority of those presenting with a thyroid nodule however 
have benign disease. The clinical importance of thyroid nodules is primarily the need 
to exclude thyroid cancer which occurs in 7-15% of cases (Tan and Gharib 1997; 
Hegedus 2004). 
The causes of thyroid nodules are listed in Table 1.1 (Gharib, Papini et al. 2006) 
 
Table 1.1 Causes of Thyroid Nodules  
 
• Benign nodular goitre 
• Chronic lymphocytic thyroiditis 
• Simple or haemorrhagic cysts 
• Follicular adenomas 
• Sub-acute thyroiditis 
• Papillary carcinoma 
• Follicular carcinoma 
• Hurthle cell carcinoma 
• Poorly differentiated carcinoma 
• Medullary carcinoma 
• Anaplastic carcinoma 
• Primary thyroid lymphoma 
• Sarcoma, teratoma, and miscellaneous 
tumors 





1.1.1 Clinical evaluation and Investigation 
Thyroid nodules are often accidental findings during clinical examination or on 
imaging for unrelated reasons (Gough, Scott-Coombes et al. 2008). Most patients 
with thyroid nodules do not have any symptoms. In symptomatic patients, a detailed 
history and examination will help guide further investigations. History should include 
a change in nodule size, rate of growth, previous head and neck irradiation and a 
family history of thyroid diseases (Yeung and Serpell 2008). Other associated 
symptoms include difficulty in swallowing or breathing which is suggestive of 
compressive effect from the thyroid swelling (Eng, Quraishi et al. 2010). Hoarse voice 
is a strong indication of recurrent laryngeal nerve involvement and malignancy (Ross 
2003). Clinical examination of the neck should include palpation of the thyroid gland 
to determine the characteristics namely the size, consistency, mobility, single nodule 
or multinodular and for palpable cervical lymphadenopathy (Eng, Quraishi et al. 
2010). Clinical features which are associated with increased probability of 
malignancy in a thyroid nodule include (Perros, Boelaert et al. 2014)- 
 
• Age less than 20 or older than 60 years 
• Firmness of the nodule on palpation 
• Rapid growth 
• Fixation to adjacent structures 
• Vocal cord paralysis 
• Regional lymphadenopathy 
• History of neck irradiation 
• Family history of thyroid cancer 
 
According to British Thyroid Association (BTA), patients with a thyroid nodule 
associated with any of the following will need urgent investigation (Perros, Boelaert 
et al. 2014); 
• Unexplained hoarseness or voice changes associated with a goitre 
• Thyroid nodule in a child 
• Cervical lymphadenopathy associated with a thyroid mass (usually deep cervical 
or supraclavicular region) 
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• A rapidly enlarging, painless, thyroid mass over a period of weeks (a rare 
presentation of thyroid cancer and usually associated with anaplastic thyroid 
cancer or thyroid lymphoma). 
 
1.1.2 Biochemical Evaluation 
Functional status of the thyroid gland should be assessed as part of the initial 
investigation of thyroid nodules. Tests include serum thyroid-stimulating hormone 
(TSH), free thyroxine (T4), and free tri-iodothyronine (T3). Serum Thyroglobulin (Tg) 
can be elevated in most thyroid diseases and is therefore not recommended as a 
routine initial assessment of thyroid nodules (Haugen, Alexander et al. 2016). 
If the serum TSH is subnormal, a radionuclide thyroid scan should be obtained to 
document whether the nodule is hyperfunctioning (hot), isofunctioning (warm), or 
non-functioning (cold) (Gharib and Papini 2007).  
Hyperthyroidism in the setting of thyroid nodules may suggest the presence of one 
or more hyper-functioning (autonomous) adenomas and the risk of malignancy in 
such nodules is less than 1% (Cases and Surks 2000). Since hyper-functioning nodules 
rarely harbour malignancy, no cytologic evaluation is necessary. If overt or subclinical 
hyperthyroidism is present, additional evaluation is required (Haugen, Alexander et 
al. 2016). A higher serum TSH level is associated with increased risk of malignancy in 
a thyroid nodule as well as more advanced stage thyroid cancer (Haymart, 
Repplinger et al. 2008). Patients with a nodule and normal thyroid function tests 
(euthyroid) may have thyroid cancer and should have further investigations (Perros, 
Boelaert et al. 2014).  
 
Thyroid antibodies such as thyroid peroxidase and anti-thyroglobulin antibodies are 
found in most patients with Graves’ disease or Hashimoto’s thyroiditis. TSH receptor 
autoantibodies are detectable in majority of patients with Graves’ disease.  
In patients with a family history of Medullary Thyroid Carcinoma and Multiple 
Endocrine Neoplasia (MEN) type II, calcitonin levels are also performed as part of the 




1.1.3 Imaging Modalities for Thyroid Nodule 
 
Thyroid Scintigraphy 
Thyroid Scintigraphy is a procedure producing images of the thyroid gland obtained 
within 15–30 min after intravenous injection of Tc-99m pertechnetate isotope or 3–
24 hours after the oral ingestion of radioactive Iodine131. It has been relied upon in 
the past to assist in risk stratification of nodules as being benign or malignant based 
on their ability to take up the isotope. Depending on the pattern of uptake, nodules 
are classified as hyper-functioning (hot), hypo-functioning (cold), or normal 
functioning (warm). Hot nodules are seen in about 5% of scans and are malignant in 
5% of cases (Wong and Wheeler 2000). Approximately 80%–85% of nodules are cold 
and 10%–15% of these are malignant (Meier and Kaplan 2001).  
Primary or secondary carcinomas of the thyroid almost invariably appear as 
nonfunctioning (cold) areas on the images (Mettler 2012), however most more than 
90% of the 'cold' lesions are due to benign processes (eg. adenoma, thyroiditis, cyst 
etc). However, if a ‘cold’ nodule is found on thyroid scan, further investigation such 
as ultrasound and fine needle biopsy are recommended. 
 
Ultrasound Scan (USS) 
 
USS forms part of the initial investigation of thyroid nodule along with clinical 
examination and Fine Needle Aspiration Cytology (FNAC).  
USS is readily available, non-invasive and an inexpensive investigation. All patients 
with thyroid nodule should undergo ultrasound evaluation of the nodule, thyroid 
gland, and cervical lymph nodes. It is helpful in identifying the nodules on which 
FNAC is necessary and also consistently increases the yield of diagnostic FNAC 
(Cesur, Corapcioglu et al. 2006; Hambly, Gonen et al. 2011). 
USS helps to differentiate benign from malignant nodules. However, no single 
feature is diagnostic (Perros, Boelaert et al. 2014). USS features indicative of benign 








A graphic representation of the recognised signs that can be used to classify thyroid 
nodules is shown in Fig 1.1 (Perros, Boelaert et al. 2014). The description of the 
classification of thyroid nodules on ultrasound scan (U1-U5) is shown in Table 1.3 
(Perros, Boelaert et al. 2014). As is evident from the table, it is used to differentiate 
between benign and malignant nodules. Such a classification system for the 
prediction of malignancy helps to determine whether a FNAC should be performed  












































(a) halo, iso-echoic / mildly hyper-echoic 
(b) cystic change +/- ring down sign (colloid) 
(c) micro- cystic / spongiform 
(d & e) peripheral egg shell calcification 




(a) homogenous, hyper-echoic (markedly), solid, halo (follicular lesion). 
(b) ? hypo-echoic, equivocal echogenic foci, cystic change 




(a) solid, hypo-echoic (cf thyroid) 
(b) solid, very hypo-echoic (cf strap muscle) 
(c) disrupted peripheral calcification, hypo-echoic 
(d) lobulated outline 
U5 
Malignant 
(a) solid, hypo-echoic, lobulated / irregular outline, 
      micro-calcification (? Papillary carcinoma) 
(b) solid, hypo-echoic, lobulated/irregular outline, globular 
     calcification (? Medullary carcinoma) 
(c) intra-nodular vascularity 
(d) shape (taller >wide) (AP>TR) 








1.1.4 Fine Needle Aspiration Cytology (FNAC) 
 
FNAC forms part of the triple assessment of thyroid nodule. It is the procedure of 
choice in the workup of thyroid nodules (Cooper, Doherty et al. 2006). It is also a  
cost effective pre-operative investigation for thyroid nodules (Bajaj, De et al. 2006).  
It helps to diagnose a benign nodule and provide definite diagnosis for some thyroid 
malignancies enabling one stage therapeutic surgery (Perros, Boelaert et al. 2014). 
However, there are some limitations of FNAC as indicated below; 
1. High rate of inadequate/unsatisfactory samples 
2. Inability to distinguish between non-neoplastic, benign and malignant 
follicular lesions (Pauzar, Staklenac et al. 2010)  
3. Difficulty in detecting follicular variant of papillary thyroid carcinoma (Chang, 
Lin et al. 2006).  
 
USS guided FNAC samples have increased accuracy (Cai, Valiyaparambath et al. 2006; 
Nixon, Ganly et al. 2010) and reduced rates of unsatisfactory samples (Cesur, 
Corapcioglu et al. 2006). It is essential that adequate material is obtained for 
diagnosis and microscopy is performed by experienced pathologists (Porterfield, 
Grant et al. 2008). Aspiration should be ideally be performed by adequately trained 
personnel with expertise in thyroid disease (Perros, Boelaert et al. 2014). Reporting 
of the cytology samples in the United Kingdom is performed according to Royal 
College of Pathologists guidance using the Thy classification (Cross P 2016) as 











Table 1.4: Summary of Classification of thyroid nodules on cytology and recommended       
actions (Eng, Quraishi et al. 2010; Perros, Boelaert et al. 2014) 
 





insufficient sample. Cyst 
containing colloid or 
histiocytes only, in the 
absence of epithelial cells 
To repeat FNAC. 
Ultrasound guidance may 
help. If cyst aspirated to 
dryness with no residual 
swelling, clinical/ 
ultrasound follow-up 




Cyst containing benign 
epithelial cells. 
 
Repeat FNAC in 3-6 
months. Two non-
neoplastic results 3-6 





USS assessment+/- repeat 
FNA. MDT discussion 
 
Thy3f 
Follicular neoplasm or 
follicular variant of 
papillary thyroid 




Thy 4 Suspicious of malignancy. 
MDT discussion - surgical 




Diagnostic of malignancy MDT discussion - surgical 




The categories can provide useful information of the likelihood of their malignant 
potential. As the Thy categories increases from 1-5, so does the malignant potential. 
In Thy 1, malignancy can be found in nodules in 4.5–8.5% of cases (Orija, Pineyro et 
al. 2007; Al Maqbali, Tedla et al. 2012). The risk is higher (14.3%) if the lesion is cystic 
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(Garcia-Pascual, Barahona et al. 2011). Thy 3 cases can have malignancy rate of 9.5-
43% especially with suspicious USS features (Maia, Matos et al. 2011; Wang, 
Friedman et al. 2011). Thy 4 cytology is associated with malignant histology in about 
68–70% (Wu, Jones et al. 2006) cases. The likelihood of a malignancy for Thy 5 is 
100%, although rates of 98-99% have been reported (Jo, Stelow et al. 2010; Wang, 
Friedman et al. 2011).  
Another method of thyroid nodule cytology classification is the Bethesda system 
described initially by National Cancer Institute Thyroid Fine-Needle Aspiration State 
of the Science Conference in 2007 (Crippa, Mazzucchelli et al. 2010). It is also 
recommended by the American Thyroid Association (ATA). The two systems have 
comparable categories as described in Table 1.5.   
 
Table 1.5 Comparison of Bethesda categories and the BTA classification 
Bethesda Diagnostic Category British Thyroid Association 
I Non-diagnostic or 
unsatisfactory 
Thy 1 Non-diagnostic 
II Benign Thy 2 Non-neoplastic 
 
III 
Atypia of undetermined 
significance or follicular 









Follicular neoplasm or 
suspicious of follicular 
neoplasm 
Thy 3f Follicular neoplasm 
suspected 
V Suspicious of Malignancy Thy 4 Suspicious of 
Malignancy 







1.1.5 USS Elastography 
 
Conventional USS is still the first line investigation in thyroid nodules but there has 
been considerable variation in its diagnostic performances (Park, Kim et al. 2009; 
Moon, Baek et al. 2011). Elastography is a dynamic technique that uses USS to 
provide an estimation of tissue stiffness by measuring the degree of distortion under 
the application of an external force (Rago, Santini et al. 2007). It is applied to study 
the hardness and elasticity of nodules to differentiate malignant from benign lesions 
(Cochlin, Ganatra et al. 2002).  
Its clinical application in thyroid nodes was first reported by Rago et al. (Rago, Santini 
et al. 2007) using a five-point scale described  originally by Ueno and colleagues 
(Ueno E 2004).  A score of 1 is defined as elasticity in the whole nodule, 2 as elasticity 
in a large part of the nodule, 3 as elasticity only at the peripheral part of the nodule, 
4 as no elasticity in the nodule, and 5 as no elasticity in the nodule and in the 
posterior shadowing (Rago, Santini et al. 2007) . Another scoring system was 
described by Asteria and colleagues (Asteria, Giovanardi et al. 2008). They defined a 
score of 1 as elasticity that is entirely soft in the nodule, 2 as mostly soft in the 
nodule, 3 as mostly hard in the nodule, and 4 as entirely hard in the nodule (Asteria, 
Giovanardi et al. 2008).  Based on these scoring systems, sensitivity to detect thyroid 
malignancy has been found to be between 94-97% and specificity between 81-100% 
(Rago, Santini et al. 2007; Asteria, Giovanardi et al. 2008). 
 Moon and colleagues (Moon, Sung et al. 2012) evaluated the role of elastography as 
an adjunctive tool to conventional USS in 676 patients with 703 solid nodules. In 
their study, neither elastography nor the combination of elastography and gray-scale 
USS showed better performance for diagnosing thyroid cancers compared with 
conventional US. Elastography has shown to be a promising technique in breast (Lee, 
Chang et al. 2014) and liver imaging (Kim, Lee et al. 2013). Addition of elastography 
to conventional USS should improve the diagnostic performances, however the 
results are conflicting of its additional value in predicting thyroid malignancies 
(Bhatia, Tong et al. 2012; Kim, Kim et al. 2013; Russ, Royer et al. 2013). Therefore, 
the value of elastography in the routine in the assessment of thyroid nodules needs 
to be established.  
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1.1.6 Imaging Modalities in Thyroid Carcinoma   
For any cancer, it is important to have accurate staging to plan treatment as it   
impacts on the long-term outcomes and survival. In PTC, the importance of a 
thorough preoperative evaluation and subsequent neck dissection to an appropriate 
extent during initial surgery has been emphasized in many studies (Chow, Law et al. 
2003; Mazzaferri 2009).   
 
Ultrasound Scan (USS) 
The role of USS in triple assessment of thyroid nodules and the characteristic 
features seen on USS have been described in above chapter.  
USS features of PTC include a solid hypoechoic nodule with a well or poorly defined 
margin and small foci of punctate calcification (Appetecchia and Solivetti 2006). PTC 
occasionally shows cyst formation as the dominant feature (Yuan, Chiou et al. 2006). 
Medullary carcinoma shows punctate calcification; calcification is however rare in 
follicular carcinoma. Anaplastic carcinomas are usually large necrotic tumours that 
extend outside the thyroid gland (Kebebew, Greenspan et al. 2005).  
 
CT and MRI Scans 
Computed tomography (CT) and Magnetic Resonance Imaging (MRI) are inferior and 
less sensitive to ultrasound in the investigation of thyroid cancer (Chaudhary and 
Bano 2012). Small tumours and thyroid nodules readily identified by ultrasound may 
be undetectable by these imaging modalities (King, Ahuja et al. 2000; Shetty, Maher 
et al. 2006).  There are no definite CT features that distinguishes benign from 
malignant lesions and it underestimates nodularity (Shetty, Maher et al. 2006). 
When found on CT, punctate calcification or cystic components may be detected 
(Shetty, Maher et al. 2006), while on MRI the cystic components show a high T1 
signal intensity. 
The main role of CT and MRI is to demonstrate extra-thyroidal tumour extension, 
spread of disease into the mediastinum or retro-tracheal region and detecting 
pulmonary and hepatic metastasis which is essential in staging of the disease 
(Chaudhary and Bano 2012; Perros, Boelaert et al. 2014). CT and MRI are also 
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recommended to evaluate occult metastases in post-thyroidectomy cases with 
elevated serum thyroglobulin (Tg) levels and negative USS finding (Cooper, Doherty 
et al. 2009). 
 
131/123I whole body scan (WBS) 
 
131/123I whole body scan serves as an adjunct to clinical evaluation and serum Tg 
testing following thyroidectomy and ablative 131I therapy (Taylor, Hyer et al. 2004) . It 
is used to detect residual loco-regional disease in the neck and distant metastases 
usually after surgery has been performed (King 2008). A positive diagnostic scan may 
demonstrate persistent disease following ablation (Grigsby, Baglan et al. 1999). In 
the UK, 131I WBS has been used to assess the success of Radio-iodine Remnant 
Ablation (RRA) with stimulated thyroglobulin (Tg) (Perros, Boelaert et al. 2014). In 
recent years, stimulated Tg and specialised USS (Torlontano, Crocetti et al. 2006) has 
been favoured as a means of assessing RRA success without the need for diagnostic 
131I WBS (Schlumberger, Berg et al. 2004; Sherman 2013). 
 
 
F-18 FDG PET/CT (Positron Emission Tomography/Computed Tomography) 
 
18FDG-PET (2-deoxy-2-_F-18_fluoro-D-glucose) is an integral part of investigation for 
many cancers such as lymphoma, melanoma, metastatic gastro-intestinal, lung, and 
head and neck cancer (Mosci and Iagaru 2011). However, it is not recommended as a 
routine investigation in the initial assessment of well differentiated thyroid cancer 
(Haugen, Alexander et al. 2016). Its main role is in investigation of persistent or 
recurrent disease. One scenario where its use is well established is in patients 
presenting with elevated Tg levels and negative radioactive iodine scan (Fletcher, 
Djulbegovic et al. 2008; Chaudhary and Bano 2012). 
18FDG-PET is useful in differentiating incidentaloma (focal uptake) from thyroiditis 
and hypothyroidism (diffuse uptake); and malignant thyroid which shows a very high 
FDG activity approaching 100% (de Geus-Oei, Pieters et al. 2006; Soto, Halperin et al. 
2010). 18FDG-PET has also been found to be the most accurate in detecting recurrent 
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or metastatic medullary thyroid carcinoma with an elevated calcitonin levels (Szakall, 
Esik et al. 2002; Iagaru, Masamed et al. 2007; Chaudhary and Bano 2012). 
 
1.1.7 Imaging of Cervical Lymph Nodes 
Ultrasound Scan (USS) 
USS is commonly used and is the imaging modality of choice in the pre-operative 
evaluation of cervical Lymph Nodes (Watkinson, Franklyn et al. 2006). It is 
recommended by various organisations including the American Thyroid Association 
(Cooper, Doherty et al. 2009). The main current use of US is to identify the presence 
of suspicious LN to guide FNA which in turn will help to differentiate between benign 
and malignant LN. 
Features which are suspicious of metastatic LN are (Kim, Park et al. 2008; Sugitani, 
Fujimoto et al. 2008) are as follows: 
a) clear hypo-echoic or in-homogenous pattern  
b) irregular cystic appearance  
c) presence of internal micro-calcification and  
d) rounded shape with increased antero-posterior diameter 
However the US features of metastatic LN are not standardised (Kessler, Rappaport 
et al. 2003) and the accuracy of differentiation can be low (Rosario, de Faria et al. 
2005). Ultrasound-guided biopsy improves diagnostic accuracy, however in patients 
especially with PTC multiple very small nodes are found and unless punctate 
calcification is identified, it can be difficult to establish a pre-operative diagnosis 
(King 2008).  
 
CT and MRI scan 
 
Computerised Tomography (CT) is also used in pre-operative evaluation of cervical 
LN although not routinely employed. However USS is considered better than CT to 
characterize features of metastatic LN as small as 5 mm in diameter due to its high-
resolution images (Na, Choi et al. 2015). 
Features which are suspicious of LN metastasis on CT are as follows (Som, Brandwein 
et al. 1994; Kim, Park et al. 2008) 
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a) cystic change 
b) calcification 
c) hyperenhancement  
d) central necrosis 
The following features seen on MRI are considered suspicious of metastatic disease 
(Gross, Weissman et al. 2001; Liu, Xun et al. 2014) 
a) Long-diameter≥10 mm with high T2 weighted signal intensity 
b) Short diameter 
c) Central Necrosis or cystic degeneration  
d) Enhancing lesions  
e) Clustering 
f) Fusion 
A combination of USS, CT and MRI is advised in the assessment of thyroid cancer  

















1.2 Thyroid Carcinoma 
1.2.1 Introduction 
Thyroid cancer is the most common malignancy of the endocrine system (Hundahl, 
Fleming et al. 1998). It accounts for about 1% of all cancers around the world with 
over 140,000 new cases every year (Parkin, Bray et al. 2005). It’s incidence has 
continuously increased all over the world (Curado M. P 2007). In Great Britain, 
incidence rates have more than doubled from 1.5 to 3.1 per 100,000 over the last 
four decades (Compeau, Tyrwhitt et al. 2009). Increased incidence of thyroid cancer 
has been shown in certain regions of the pacific (Le Vu, de Vathaire et al. 2000; 
Truong, Rougier et al. 2007) and in the last few decades in industrialized nations like 
France (Reynolds, Weir et al. 2005; Davies and Welch 2006).  
The exact reasons for the global rise of thyroid cancer remain unclear; there is an 
argument whether this is a true or an apparent increase. Most experts believe that 
the increased number of new cancers is due to the increased diagnostic intensity 
especially of small tumours (Davies and Welch 2006; Grodski, Brown et al. 2008). 
Incidental detection of thyroid tumours has also increased in recent years from 
increasing use of Doppler examination of the neck vessels and other imaging 
procedures like PET scans (Yun, Noh et al. 2010; Nilsson, Arnberg et al. 2011).  
There are others who believe that when improved detection is the only cause, the 
increase of small and early stage tumours should be accompanied by a progressive 
decline of larger and more advanced tumours (Pellegriti, Frasca et al. 2013). 
However this is not the case and the rise of thyroid cancer incidence whilst most 
prominent for small tumours, has occurred across all tumour sizes and stages, 
suggesting that increased detection is not the only cause (Enewold, Zhu et al. 2009; 
Rego-Iraeta, Perez-Mendez et al. 2009).  Increased exposure to radiation is the most 
likely contributing factor for any true increase in the incidence but also other 
environmental carcinogens and lifestyle changes are a possibility (Pellegriti, Frasca et 
al. 2013). It is the fifth most common cancer in women (Jemal, Siegel et al. 2010); 
and in some countries like Italy, it is the second most common cancer in women 




1.2.2 Classification of Thyroid Cancer 
 
I. Follicular Epithelial Cell Origin 
A. Differentiated Thyroid Cancer 
1. Papillary Thyroid Cancer (PTC) 
a) Classic morphology 
b) Encapsulated variant 
c) Follicular variant 
d) Aggressive variants 
 1. Diffuse sclerosing variant 
 2. Tall cell variant 
 3. Columnar Cell variant 
2. Follicular Thyroid carcinoma (FTC)  
 a) Classic morphology (‘follicular carcinoma’) 
     -minimally invasive versus widely invasive 
 b) Hurthle Cell variant 
    - minimally invasive versus widely invasive 
B) Poorly differentiated thyroid cancer (Insular Carcinoma) 
C) Undifferentiated thyroid cancer (Anaplastic Carcinoma) 
II. Parafollicular C-Cell origin 
Medullary Thyroid Carcinoma (MTC) 











1.2.3 Differentiated Thyroid Carcinoma 
 
This includes Papillary and Follicular Thyroid Carcinomas. Papillary Thyroid 
Carcinoma (PTC) is the most common type of thyroid malignancy accounting for 
nearly 75% of all thyroid malignancies (Hundahl, Cady et al. 2000). 
 
1.2.4 Risk Factors for Differentiated Thyroid Cancer 
 
Radiation exposure 
Exposure to radiation is a proven risk factor in the aetiology of papillary thyroid 
cancer (Hunt 2009). The thyroid gland is likely to be exposed to radiation more than 
other tissues because of its position in the body and its ability to concentrate iodine 
(Pellegriti, Frasca et al. 2013). In the past, thyroid carcinomas were more frequent in 
patients treated with low dose radiation for benign head and neck disease (DeGroot 
and Paloyan 1973). During the last quarter of a century, the individual radiation dose 
has doubled in developed countries like the USA (Mettler, Bhargavan et al. 2008). 
This has been attributed  mainly due to medical diagnostic and therapeutic 
procedures (Mettler, Bhargavan et al. 2008). The increased use of CT scans in 
childhood has been attributed to a potential increase in thyroid cancer (Mazonakis, 
Tzedakis et al. 2007; Berrington de Gonzalez, Mahesh et al. 2009). The use of I131 
either for diagnostic reasons or therapeutic purposes in hyperthyroidism is another 
source of thyroid irradiation and has shown to cause a small increase in thyroid 
cancer (Franklyn, Maisonneuve et al. 1998; Metso, Auvinen et al. 2007). Due to the 
increase in the use of radiotherapy for many cancers, survivors have been found to 
develop PTC in later life (Chow, Friedman et al. 2009).  
After the nuclear bomb attacks in World War II, there have been reports of increased 
incidence of PTC in survivors (Wood, Tamagaki et al. 1969; Nakachi, Hayashi et al. 
2008). Unusual thyroid tumours have also been reported in individuals living near 
areas near nuclear bomb test sites (Anspaugh, Ricker et al. 1990; Takahashi, 
Schoemaker et al. 2003). Similar reports of increased incidence of thyroid cancer 
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have been well documented after the Chernobyl nuclear disaster (Tronko, 
Bogdanova et al. 2010; Saenko, Ivanov et al. 2011).  
 
Iodine Deficiency and Goitre 
Thyroid stimulating hormone (TSH) is a major growth factor for thyroid follicular cells 
and iodine deficiency causes an increase level of this hormone. Some animal 
experiments have demonstrated an increase of thyroid cancer after prolonged iodine 
deficiency. However, this has not been demonstrated in humans residing in iodine 
deficient areas (Dal Maso, Bosetti et al. 2009). In iodine deficient areas, the over-all 
incidence of follicular carcinoma seems to be more than the papillary type (Feldt-
Rasmussen 2001). This shift from a follicular to a papillary histotype may be due to 
the frequency of the BRAF(V600E) mutation, a typical molecular alteration in PTC 
(Pellegriti, Frasca et al. 2013). 
Chronic iodine deficiency seems to be a risk factor for follicular thyroid cancer, and 
possibly anaplastic thyroid cancer (Besic, Hocevar et al. 2010). The major risk factor 
for goitre and nodularity is iodine deficiency, and both goitre and nodules are major 
risk factors for thyroid cancer in both men and women (Pellegriti, Frasca et al. 2013).  
One study reported a relative risk for thyroid cancer of 5.9 (95% CI 4.2–8.1) in 
individuals with a history of goitre and a much higher risk in those with a history of 
benign nodularity (Franceschi, Preston-Martin et al. 1999). Williams et.al have 
reported that dietary iodine concentrations influence the morphology of the 
papillary carcinomas (Williams, Abrosimov et al. 2008).  They found that PTC 
amongst children in iodine deficient areas showed more aggressive and less 
differentiated morphological features than those from iodide-rich areas (Williams, 
Abrosimov et al. 2008). 
 
Other Risk Factors 
Other known risk factors for thyroid cancer are non-modifiable with patient age, sex, 
ethnicity and family history serving as the strongest predictors of risk (Kitahara and 
Sosa 2016). Women have approximately 3-4 times higher incidence of thyroid cancer 
than men, this ratio has remained constant over time and across countries (Kilfoy, 
Zheng et al. 2009). This difference is more pronounced for PTC compared to other 
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histological subtypes (Kilfoy, Zheng et al. 2009). A SEER (Surveillance, Epidemiology, 
and End Results) based study from the United States found the incidence of PTC to 
be highest in Asian females, while papillary and follicular thyroid cancer were the 
highest among White males (Aschebrook-Kilfoy, Kaplan et al. 2013).  
Although vast majority of differentiated thyroid carcinomas are sporadic (Dotto and 
Nose 2008; Nose 2008), familial tumours may account for 5–15% of thyroid cancers 
(Nose 2011). They fall under a broad category named Familial Non-Medullary 
Thyroid Carcinomas (FNMTC) and are follicular cell derived neoplasms. They 
encompass a heterogeneous group of diseases including both syndromic-associated 
tumours and non-syndromic tumours based on clinic-pathologic findings (Nose 
2008). 
Dietetic factors interfering with thyroid hormone synthesis such as cruciferous 
vegetables could also affect thyroid cancer risk, however this possibility has never 
been demonstrated (Peterson, De et al. 2012). The evidences of a possible effect of 




1.2.5a Classical Papillary Thyroid Cancer 
The gross appearance of PTC is variable. Papillary carcinomas often average 2–3 cms, 
although lesions may be quite large or commonly sub-centimetre in size (LiVolsi). 
The lesions are firm and usually white in colour. There may be extensive sclerosis 
making the lesion resemble a scar especially in small lesions. In addition, cyst 
formation may be observed. Rarely lesions may be almost completely cystic, making 
diagnosis difficult (Carcangiu, Zampi et al. 1985; Baloch Z 2002). 
Microscopically papillary carcinomas share certain features (Figure 1.2). The 
neoplastic papillae contain a central core of fibro-vascular (occasionally just fibrous) 
tissue lined by one or occasionally several layers of cells with crowded oval nuclei 
(Vickery 1983; Carcangiu, Zampi et al. 1985; Baloch Z 2002). Cellular features include 
clear nuclei, nuclear grooves, and pseudo-nuclear inclusions. The tumours invade 
lymphatics leading to multifocal lesions and to regional node metastases. Venous 
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Figure 1.2 Papillary Thyroid Cancer-Finger like projections representing papillary  
growth pattern lined by neoplastic cells. 
 
1.2.5b Histo-pathological variants 
Micro-carcinomas 
Commonly known as Papillary thyroid micro-carcinoma (PTMC), they are defined by 
the World Health Organisation (WHO) as PTC less than 1.0cm in largest dimension 
(DeLellis R 2004). In recent years, it is being diagnosed with increasing frequency. 
This has been attributed to the widespread use of USS and FNAC biopsy, as well as 
the improved resolution of ultrasonography (Noguchi, Yamashita et al. 2008; Grodski 
and Delbridge 2009).  
 
Follicular variant 
The follicular variant of PTC is the second most common subtype found in 9–22.5% 
of patients with PTC (Sebastian, Gonzalez et al. 2000; Passler, Prager et al. 2003).  It 
has characteristic nuclear features of a typical PTC like nuclear clearing, grooves, and 
pseudo-inclusions in addition to a follicular growth pattern (Gupta, Ajise et al. 2012). 
These tumours can be a challenge for pathologists to diagnose accurately.  
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There are two further sub-types of the follicular variant of PTC, namely 
encapsulated and non-capsulated. Most of these are encapsulated tumors, which 
are difficult to distinguish from follicular adenomas (Gupta, Ajise et al. 2012). These 
subtypes appear to be distinct both clinically and genetically. A study showed that 
lymph node metastases were found to be 5% and 65% in encapsulated and non-




Tall Cell Variant 
The tall-cell variant (TCV) is more aggressive than classical PTC. It was first described 
by Hawk and Hazard in 1976 (Hawk and Hazard 1976).  It is an uncommon variant 
that is usually found in older patients and is associated with poor prognosis (Morris, 
Shaha et al. 2010). It is composed predominantly of tall cells with height at least 
twice width, eosinophilic cytoplasm, and basally oriented nuclei (Ghossein and Livolsi 
2008). As a variant of PTC, the characteristic nuclear features of PTC are also present.  
A meta-analysis on prognostic outcomes found that TCV recurs with 4.50 times (CI: 
2.90-6.99) greater odds than the classical variant and also had 14.28 (CI: 8.01-25.46) 
greater odds of disease-related mortality (Jalisi, Ainsworth et al. 2010). The same 
study also found that TCV had higher trends of lymph node and distant metastases 
and extra-thyroidal extension (Jalisi, Ainsworth et al. 2010).  
 
Columnar cell variant 
 
It is a rare variant of PTC accounting for 0.15% to 0.2% of all tumours; some authors 
group them together with TCV (Wenig, Thompson et al. 1998). In this variant, cells 
are tall with elongated hyperchromatic pseudostratified nuclei which differ from TCV 
cells in that they lack the cytologic nuclear features characteristic of TCV (Silver, 
Owen et al. 2011). Columnar cell variant are aggressive due to its rapid growth, high 





Diffuse Sclerosing Variant 
Diffuse sclerosing variant of PTC is characterized by dense sclerosis, patchy 
lymphocytic infiltration, and abundant psammoma bodies (Fujimoto, Obara et al. 
1990). Both lobes of the thyroid are usually involved which often show a background 
of chronic lymphocytic thyroiditis. These variety is more common in younger patients 
between 15 and 30 years of age (Koo, Hong et al. 2009). 
There are mixed reports regarding the aggressiveness and outcomes of this variant 
of PTC. Most authors have found high incidence of cervical metastasis, extracellular 
spread, local recurrence and distant metastases with decreased disease-free survival  
(Carcangiu and Bianchi 1989; Sywak, Pasieka et al. 2004; Falvo, Giacomelli et al. 
2006). Some smaller series however have found no difference in the outcomes 
(Fujimoto, Obara et al. 1990; Albareda, Puig-Domingo et al. 1998). 
Given the infiltrating nature of the disease and the propensity for lymph node 
metastases, more aggressive management of this variant with total thyroidectomy 
and appropriate lymphadenectomy is recommended for all patients (Silver, Owen et 
al. 2011).  
 
Follicular Thyroid Carcinoma 
Follicular Thyroid Carcinoma (FTC) is defined by WHO as a malignant epithelial 
tumour showing follicular cell differentiation and lacking the diagnostic nuclear 
features of papillary thyroid carcinoma (Sobrinho-Simoes, Eloy et al. 2011).  
Follicular Thyroid Carcinomas are solid encapsulated tumours with gray to brown 
colour at the cut surface (Sobrinho-Simoes, Eloy et al. 2011). They usually occur as 
single tumours; multi-focality and recurrence in the residual parenchyma after 
treatment is uncommon. There are two sub-types of FTCs namely minimally and 
widely invasive. Macroscopically minimally invasive FTCs are indistinguishable from 
Follicular Adenomas (FA), except for capsular characteristics which tends to be 
thicker and more irregular in FTC than in FA (Rosai 2004). Widely invasive FTCs may 
occur as partially encapsulated tumours with extensive penetration of the capsule or 




FTC often presents with more advanced disease and a higher incidence of distant 
metastases because of the propensity of vascular invasion (Lo, Chan et al. 2005). 
Lymph node metastasis is uncommon in FTC with an average incidence of about 10% 
(Thompson, Wieneke et al. 2001). 
The prognosis of FTC depends on several factors: age of the patient, size and staging 
of the tumour, completeness of surgery and responsiveness to radioactive iodine. 
Age more than 45, male gender, extrathyroid invasion, bigger tumour size (>4cms), 
vascular invasion and presence of distant metastasis are recognized risk factors for 
poorer prognosis (Lang, Lo et al. 2007; Pisanu, Di Chiara et al. 2010).  
 
 
Oncocytic/Hurthle Cell Variant 
Hurthle cell carcinomas (HCC) account for about 5% of all well-differentiated 
carcinomas (Bhattacharyya 2003). Once considered to a subset of FTC, genomic 
dissection has revealed a unique class of thyroid malignancy distinct from papillary 
and follicular thyroid cancer (Ganly, Ricarte Filho et al. 2013). Because of the rarity, 
large scale data on this type of tumour is limited. These variants have the typical 
molecular features of their conventional counterparts of PTC and FTC, however they 
demonstrate a lesser ability to concentrate iodine and thus are less responsive to 
radioactive iodine therapy (Cannon 2011). HCC are commonly found in older 
patients, those who have undergone thyroid irradiation, long-standing nodular 
goiters, Graves' disease, and Chronic Lymphocytic Thyroiditis (Cannon 2011). 
It can be difficult to determine if a Hurthle cell lesion is benign or malignant 
(Montone, Baloch et al. 2008).  Although larger lesions have a higher incidence of 
malignancy, size in itself is not a criterion. The main criteria for malignancy include 
the presence of capsular and or vascular invasion (Montone, Baloch et al. 2008). 
Hurthle cell carcinomas do metastasize to the lymph nodes in about 3-25% 
(Guerrero, Suh et al. 2010); in addition they can spread to the lungs, liver and bone 
(Har-El, Hadar et al. 1986). There is conflicting evidence about the prognosis of HCC 
compared to the other types of differentiated thyroid carcinoma and FTC 




1.2.6 Prognostic Factors for Papillary Thyroid Cancer 
 
Age  
It is a major prognostic factor in thyroid cancer and features in all prognostic 
scoring.  Patients younger than 45 years of age do remarkably well compared with 
those older than 45 years (Shaha 2004).  The mortality rates increases after 60 years 
of age (Mazzaferri and Jhiang 1994). 
 
Gender 
The importance of gender in PTC prognosis has been widely discussed in literature. 
Studies have shown that women have a higher incidence of thyroid nodules 
compared to men (Morganti, Ceda et al. 2005; Frates, Benson et al. 2006). 
However, the incidence of cancer in nodules tends to be higher in men (Machens, 
Hauptmann et al. 2006). Arguably women with thyroid cancer tend to have a better 
prognosis than men although the cause of this is not well established. One of the 
possible explanations for this could be because of differences in screening rates, 
such as the greater tendency of men to seek medical attention later than females 
(Toniato, Boschin et al. 2008). 
Another possible explanation could be that papillary thyroid cancer tends to be  
diagnosed at an earlier age in females than in males (Lin, Hsieh et al. 2001). Male 
patients are higher risk of lymph node micro-metastasis (Teixeira, Teixeira et al. 
2011). Studies have also shown a significant correlation between male gender and 
lung metastasis in papillary thyroid carcinoma presenting with bilateral lateral 
cervical lymph node metastasis (Lee, Lim et al. 2011).  
 
Men tend to have higher recurrence rates and mortality (Mazzaferri and Jhiang 
1994).  This might be because men tend to have higher rates of extra-thyroidal 
invasion (51 vs 39%), greater likelihood of loco-regional lymph node involvement (40 
vs 32%) and more than twice the rate of distant metastases (9 vs 4%) (Ries LAG 
2003). A recent study found higher mortality and recurrence rates in males with PTC 
in TNM stages II to IV, suggesting the need for more aggressive surgical treatment 
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and postoperative radio-iodine therapy for this specific group of patients (Hsieh, 
Chen et al. 2012). 
 
Tumour size 
Size of the primary tumour features in most of the risk stratification systems for PTC 
namely AMES, MACIS, AGES etc. Long term survival and recurrence rates have been 
found to be worse for larger tumours. A large database study has shown ten-year 
recurrence rates increased with increasing tumour size: <1.0 cm 4.6%, 1.0- 1.9 cm 
7.1%, 2.0 -2.9 cm 8.6%, 3.0-3.9 cm 11.6%, 4.0-8.0 cm 17.2%, and >8.0 cm 24.8% (P 
<0.0001) (Bilimoria, Bentrem et al. 2007). Similarly ten-year survival rates declined 
with increasing tumour size, but survival was statistically worse only for tumours 
larger than 4.0 cm (P <0.0001): <1.0 cm 98.0%, 1.0-1.9 cm 98.4%, 2.0-2.9 cm 98.5%, 
3.0-3.9 cm 95.5%, 4.0-8.0 cm 90.5%, and >8.0 cm 81.3% (Bilimoria, Bentrem et al. 
2007). 
Other studies have also shown a linear correlation with the tumour size; there is a 
0.4% long term mortality in tumours <1.5 cm increasing to 20% in tumours >4.5cm 
(Mazzaferri and Jhiang 1994). However, outcomes depend of variety of other factors 
including overall staging, type of surgical and adjuvant treatments.  
Tumours < 1 cm i.e Papillary Thyroid Micro-carcinomas (PTMC) have a very good 
prognosis. From a recent database study looking at the outcomes of PTMC’s, disease 
-specific survivals at 10 and 15 years were 99.5% and 99.3% respectively (Yu, Wan et 
al. 2011).  
 
Histology 
Histology of the tumour is an important determinant of long-term outcome. 
Differentiated Thyroid Cancer, including PTC has the most favourable survival rates, 
while MTC and ATC have been associated with significantly poorer outcomes 
(Hundahl, Fleming et al. 1998).  
Among the histological subtypes of PTC, tall cell variant tends to present at a later 
stage and has a higher risk of loco-regional and distant relapse with worse overall 
survival compared to patients with classic PTC (Leung, Chow et al. 2008). In a large 
multicentre study looking at the PTC subtypes, follicular variant had the best 
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recurrence and mortality rates at 9.1% and 0.6% respectively. Classical PTC had 
recurrence and mortality rates of 16.1% and 2.5% whereas the tall cell variant had 
the worst figures with recurrence at 27.3% and mortality of 6.7% (Shi, Liu et al. 
2016). 
For FTC, the prognosis is generally good but the presence of metastatic disease 
makes it worse. A large study on FTC found that in patients without metastatic 
disease, 20-year disease-specific survival rates reached 80.2%, whereas for all FTC 
patients it was 73.7%. (Verburg, Mader et al. 2009). Another large study by Hundahl 
et al found a 10-year survival rate of 85% for FTC (Hundahl, Fleming et al. 1998). 
For Medullary Thyroid Carcinoma (MTC), age and stage of disease at the time of 
diagnosis has been shown to be an important factor that influences prognosis 
(Wells, Asa et al. 2015).  Studies have shown a worse disease free survival at five 
and ten years for patients <40 years as compared to >40 years of age (95 versus 
65% and 75 versus 50%, respectively) (Kebebew, Ituarte et al. 2000). 
The 10-year survival rates for patients with stages I, II, III, and IV MTC are 100, 93, 
71, and 21% respectively (Wells, Asa et al. 2015). 
 
Extra-thyroidal extension 
Extension of thyroid cancer into the surrounding tissues, oesophagus and trachea is 
associated with a high-risk of loco-regional disease recurrence (Gemsenjager, Heitz 
et al. 2001).  It is seen in as many of 30% of cases of PTC (Mazzaferri and Jhiang 
1994). Even if the spread is microscopic and beyond the capsule, it is associated with 
a higher risk of recurrent disease (Jukkola, Bloigu et al. 2004) and greater likelihood 
of lymph node metastases (Lee, Lee et al. 2008). Studies have also shown that 
positive resection margins (R1) is associated with higher rates when compared to 
negative margins (R0) (Tuttle, Leboeuf et al. 2008; Hong, Ahn et al. 2012).   
 
Lymph node metastases 
LN metastases are more common in PTC when compared to other subtypes of 
thyroid cancer. The prevalence of lymph node metastases at the initial presentation 
has varied between studies. To some extent it depends on the imaging modalities 
used and the method employed in detection. The incidence of metastases ranges 
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from 20% to 90% with an average of 60% (Rotstein 2009). Other studies have 
reported similar percentages (Ito, Higashiyama et al. 2007; Jallon, Bonnet et al. 
2009). In children, the numbers are even higher with up to 65% having central nodal 
disease at presentation (Kumar and Bal 2003). 
The clinical importance of cervical LN metastases (CLNM) is however highly 
controversial. The key question whether the presence of CLNM, or their removal, 
affects long term survival remains largely unanswered. There are some studies which 
have found no difference in survival between patients with and without lymph node 
metastases (Hay, Bergstralh et al. 1993; Hughes, Shaha et al. 1996).  
The reason for this is not fully understood. The speculation is the difference in the 
behaviour of tumour biology between thyroid and other solid cancers. Studies have 
shown that cancer cells disseminate relatively early in both lymphatic and blood 
vessels in a large proportion of adult solid cancers (Roberts, Hengesh et al. 1967; 
Griffiths, McKinna et al. 1973). These cells can be detected cytologically, yet their 
presence is not necessarily correlated with a poor outcome (Roberts, Hengesh et al. 
1967). Whilst the spread to the lymph nodes may occur readily in thyroid cancer, this 
does not translate into distant metastasis readily unlike some other solid cancers 
(Cady 1984).  
Other studies have found that their presence leads to an increased risk of recurrence 
(Ito, Higashiyama et al. 2007). A large cohort study has shown significantly reduced 
overall survival at 14 years in patients with lymph node metastasis compared to 
those with node negative disease (82 vs 79%, p-<0.05) (Podnos, Smith et al. 2005). 
 
Distant metastases 
Distant metastasis is seen in about 5-10% of patients with PTC and remains the main 
cause of mortality in patients with PTC (Benbassat, Mechlis-Frish et al. 2006; 
Durante, Haddy et al. 2006). The most common site is the lungs accounting for more 
than half of patients with distant metastases.  25% have bone involvement alone, 
20% have both lung and bone involvement, and about 5% develop distant 





1.2.7 Classification of Cervical Lymph Node Compartments 
 
The most widely used classification is that proposed by the American Joint 
Committee on Cancer (AJCC) and the American Academy of Otolaryngology- 
Head and Neck Surgery first described by Robbins (Robbins, Clayman et al. 
2002) displayed in Table 1.6. In addition to the above classification, cervical LN 
have also been classified based on axial imaging as described by Som and 
colleagues (Table 1.7) (Som, Curtin et al. 2000). 
 
Table 1.6 Clinical classification of cervical LN (Robbins, Medina et al. 1991) 
Levels Boundaries  Sub-classified and included 
Lymph nodes  
Level I Anterior belly of the digastric muscle and the 
hyoid bone. 
IA (Sub-mental). 
Between anterior and posterior bellies of 
digastric and the mandible. 
IB (Sub-mandibular)- 
Level II Upper Jugular –from the carotid bifurcation 
or the hyoid bone to the base of the skull. 
Anterior boundary is the lateral border of 
sternohyoid; posterior boundary is the 
posterior border of sternocleidomastoid. 
IIA- anterior to spinal accessory 
nerve. 
IIB- posterior to spinal 
accessory nerve. 
Level III Middle jugular- from the carotid bifurcation 
superiorly to the omohyoid muscle or 
cricothyroid notch inferiorly.  
Anterior boundary is the lateral border of 
sternohyoid, posterior boundary is the 
posterior border of sternocleidomastoid. 
None. 
Level IV Lower Jugular- omohyoid muscle superiorly 
to the clavicle inferiorly. Anterior boundary is 
the lateral border of sternohyoid, posterior 




triangle group.  
Posterior boundary is the anterior border of 
the trapezius muscle, anterior boundary is 
the posterior border of sternocleidomastoid 
VA- those located above the 
horizontal plane defined by the 
inferior border of the cricoid 
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(includes the supra-clavicular LN). cartilage. 
VB- Below the horizontal plane 
defined by the inferior border 




Hyoid bone superiorly and the carotid 
arteries laterally, the inferior border has 
been variably defined as the sternal notch or 
the innominate (brachiocephalic) artery. 
Pre-tracheal and para-tracheal 
nodes, the pre-cricoid 
(Delphian) node and the peri-
thyroidal nodes, including 
nodes along the recurrent 
laryngeal nerves. 
Level VII. Superior mediastinal. None. 
 
 
Table 1.7 Imaging based classification of cervical LN (Som, Curtin et al. 2000) 
Levels Boundaries  
Sub-classified and included Lymph 
nodes  
Level I 
Medial margins of the anterior 
bellies of the digastric muscles 
above the hyoid bone and below the 
mylohyoid muscle. 
IA (Sub-mental) 
On each side of the neck, these 
nodes lie lateral to the level IA nodes 




These nodes extend from the skull 
base to the level of the bottom of 
the body of the hyoid bone. They are 
posterior to the back of the 
submandibular gland and anterior to 
the back of the sternocleidomastoid 
muscle. 
II A-Level II nodes that lie either 
anterior, lateral, medial, or 
posterior to the internal jugular 
vein. 
II B- nodes that lie posterior to the 
internal jugular vein with a fat 
plane separating the nodes and 
the vein. 
Level III 
These nodes extend from the level of the bottom of the body of the hyoid 
bone to the level of the bottom of the cricoid arch. They lie anterior to the 
back of the sternocleidomastoid muscle. 
Level IV 
These nodes extend from the level of the bottom of the cricoid arch to the 
level of the clavicle. They lie anterior to a line connecting the back of the 
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sternocleidomastoid muscle and the posterior-lateral margin of the 
anterior scalene muscle. They are also lateral to the carotid. 
Level V Posterior 
triangle group. 
These nodes lie posterior to the back 
of the sternocleidomastoid muscle 
from the skull base to the level of 
the bottom of the cricoid arch. From 
the level of the bottom of the cricoid 
arch to the level of the clavicle as 
seen on each axial scan, they lie 
posterior to a line connecting the 
back of the sternocleidomastoid 
muscle and the posterior-lateral 
margin of the anterior scalene 
muscle. They also lie anterior to the 
anterior edge of the trapezius 
muscle. 
V A- Extend from the skull base 
to the level of the bottom of the 
cricoid arch. They are posterior 




V B- extend from the level of the 
bottom of the cricoid arch to the 
level of the sternocleidomastoid 
muscle and the posterior-lateral 
margin of the anterior scalene 






These nodes lie between the carotid arteries from the level of the bottom 
of the body of the hyoid bone to the level of the top of the manubrium 
(previously known as the visceral nodes). 
Level VII 
These nodes lie between the carotid arteries below the level of the top of 
the manubrium and above the level of the innominate vein (previously 
known as the superior mediastinal nodes). 
Supraclavicular. 
These nodes lie at or caudal to the level of the clavicle as seen on each 
axial scan and lateral to the carotid artery on each side of the neck. They 
are also above and medial to the ribs. 
Retropharyngeal. 
These nodes lie within 2 cm of the skull base and they are medial to the 
internal carotid arteries. 
 
 
1.2.8 Pattern of Metastases 
 
The head and neck contains nearly two-fifths of the lymph nodes of the whole body, 
hence has a rich lymphatic network (Grodski, Cornford et al. 2007; Grubbs, Rich et al. 
2008). The thyroid gland has an extensive lymphatic drainage which can follow a 
number of directions (Sakorafas, Sampanis et al. 2010). The risk of metastases to 
cervical LN in PTC has varied according to different studies. The incidence of LN 
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metastases has been reported to be between 20%-90% of cases (Rotstein 2009) . 
According to some reports the risk is greatest for lateral LN of levels II, III, and IV 
(Qubain, Nakano et al. 2002; Caron, Tan et al. 2006; Roh, Park et al. 2007). Overall 
central LN are more commonly involved and usually before lateral LN involvement 
(Goropoulos, Karamoshos et al. 2004). Bilateral central LN metastases is reported 
anywhere between 30-46% of patients (Noguchi, Kumaki et al. 1990; Machens, Hinze 
et al. 2002; Sadowski, Snyder et al. 2009). Other reports have suggested the ipsi-
lateral central neck as the most common site of metastatic PTC.  In about 20% of 
patients lateral LN are involved in isolation without any central LN involvement. They 
are also known as ‘skip metastases’(Machens, Holzhausen et al. 2004).  
 
Micro-Metastasis  
It is defined as histological presence of metastatic deposits <2mm in diameter in a 
lymph node (Sakorafas, Sampanis et al. 2010) . The incidence varies according to the 
technique used to identify them. The incidence rates described in literature has 
varied between 50-66% (Qubain, Nakano et al. 2002; Cranshaw and Carnaille 2008).   
 
1.2.9 Cervical Lymph Node Dissection 
 
Cervical LND in PTC has evolved from radical surgery to more refined procedures 
with  fewer complications. It is important to understand some of the surgical 
procedures that are practised.  A summary of individual procedures is described 
below.  
 
Radical Neck Dissection 
This procedure was initially described in 1906 by George Crile (Soto-Ruiz and Varon 
2009). This involves removal of all the lymph nodes in the neck along with three 
important anatomic structures namely the sternocleidomastoid muscle, the internal 
jugular vein and the spinal accessory nerve. This has major side effects including 
dysmorphy and shoulder dysfunction due to sacrifice of the spinal accessory nerve. 
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Vagus nerve injuries can occur resulting in significant dysphonia from ipsilateral vocal 
cord paralysis and dysphagia with pooling of secretions from pharyngeal paralysis. 
 
Extended Radical Neck Dissection 
In this, additional lymph node groups or non-lymphatic structures relative to the 
radical neck dissection are removed. Other LN groups may include superior 
mediastinal, retropharyngeal, peri-pharyngeal, post-auricular etc. Other non-
lymphatic structure may include vagus nerve, hypoglossal nerve or external carotid 
artery. It is a more aggressive procedure than radical neck dissection.   
 
Modified Radical Neck Dissection 
First described in 1962 by Oswaldo Suarez, an Argentinian surgeon (Byers 1991) this 
procedure has gained popularity in Europe and in the United States of America. 
Here, dissection of Levels II-V cervical LN is done with sparing of the following 
structures: sternocleidomastoid muscle, internal jugular vein or spinal accessory 
nerve (CN XII) (Sitges-Serra, Lorente et al. 2013). Depending on which non-lymphatic 
structure is preserved, MRND is further subdivided into type I (preservation of the 
spinal accessory nerve), type II (preservation of the spinal accessory nerve and 
internal jugular vein), and type III (preservation of the spinal accessory nerve, 
internal jugular vein, and sternocleidomastoid muscle) (Sakorafas, Sampanis et al. 
2010).  
 
Selective Neck Dissection 
This involves preservation of one or more lymph node groups routinely removed in 
the radical neck dissection. The procedures are based on a ‘compartment-oriented’ 
dissection of LN. For example the central compartment LN dissection would involve 
removal of LN in level VI with preservation of the recurrent laryngeal nerve and at 
least one parathyroid gland.  
 
Berry Picking  
In this procedure, only suspicious and enlarged lymph nodes are removed. This type 
of surgery cannot achieve complete removal of metastatic disease and results in a 
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high incidence of recurrent disease requiring further surgery (Musacchio, Kim et al. 
2003). The incidence of recurrences after this procedure has been reported to be as 
high as 86% (Davidson, Park et al. 2008). Hence this procedure is now of historical 
importance only. 
 
1.2.10 Terminology of Neck Dissection 
 
Central lymph node dissection is the removal of the level VI LN that lies in a central 
position in the neck. Level VI LNs includes pre-tracheal and para-tracheal nodes, the 
pre-cricoid (Delphian) node and the peri-thyroidal nodes including nodes along the 
recurrent laryngeal nerves (White, Gauger et al. 2007; Carty, Cooper et al. 2009).  
Lateral lymph node dissection (lateral LND) is defined as removal of the jugular 
lymph nodes corresponding to lymph nodes in level II-IV.(Robbins, Shaha et al. 
2008; Cooper, Doherty et al. 2009). 
There is now a consensus amongst leading endocrine organisations namely ATA 
(American Thyroid Association), AAES (American Association of Endocrine Surgeons) 
and AAO (American Academy of Otolaryngology) regarding the terminology used for 
neck dissection in thyroid cancer. 
A ‘therapeutic compartment neck dissection’ also known as ‘selective’ implies that 
nodal metastasis is apparent clinically (preoperatively or intra-operatively) or by 
imaging (Carty, Cooper et al. 2009). In  this all apparent LN, fatty tissue and fascia are 
removed from an anatomically defined compartment. 
A ‘prophylactic’, also known as ‘elective’ compartment dissection implies nodal 
metastases are not detected clinically or by imaging pre-operatively (Carty, Cooper 
et al. 2009). This means removal of all lymph nodes from an anatomically defined 
compartment as part of the surgical procedure. 
 
1.2.11 Staging of Papillary Thyroid Cancer 
 
The most widely used and accepted staging of PTC is the TNM classification provided 
by the Union for International Cancer Control (UICC) and used by American Joint 
Committee on Cancer (AJCC) as shown in Table 1.8. 
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Table1.8  Staging of Papillary Thyroid Cancer (Edge SB 2010) 
 
T- Primary tumour 
Tx Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
T1 <2 cm or less, limited to thyroid. 
T1a <1cm. 
T1b >1 cm but < 2cm. 
T2 >2 cm but <4 cm, limited to thyroid. 
T3 > 4 cm, limited to thyroid or any tumour with minimal extra-thyroidal 
extension. 
T4a: Extends beyond thyroid capsule and invades the following- subcutaneous soft 
tissues, larynx, trachea, oesophagus and recurrent laryngeal nerve. 
T4b Invades prevertebral fascia, mediastinal vessels or encases carotid artery. 
N- Regional Lymph Nodes. 
Nx Regional LN cannot be assessed. 
N0 No regional LN metastases. 
N1 Regional LN metastases. 
N1a Metastases in Level VI. 
N1b Metastases in other unilateral, bilateral or contralateral cervical LN 
(Levels I, II, III, IV or VI). 
M- Distant Metastasis. 
M0 No distant Metastases. 
M1 Distant Metastases. 
 
Once the T, N and M values are determined, grouping from I to IV is done as shown 











Table 1.9 Group Staging- Papillary Thyroid Cancer   
 
Under 45 years  
Stage I Any T Any N M0 
Stage II Any T Any N M1 
45 years and older 
Stage I T1a, T1b N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T-3 N1a M0 
Stage IVA T-3 N1b M0 
 T4a N0 M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
 
As is evident from the Table 1.9, thyroid cancers are grouped in stages in a way that 
also considers the subtype of cancer and the patient's age. There are several systems 
which aim to stratify thyroid cancer patients according to risks to predict the 
treatment and outcomes. The most commonly used in PTC is the MACIS system 
(Table 1.10). 
 
Table 1.10 Risk Stratification systems for Differentiated Thyroid cancer (Sakorafas, 
Sampanis et al. 2010) 



































1.3 Treatment of Differentiated Thyroid Carcinoma 
The pre-operative assessment and imaging methodology employed in the evaluation 
of thyroid cancer has been discussed in the previous chapters.   
The general principles and guidelines for surgery in thyroid cancer are described 
below. The terminology related to thyroid cancer surgery as recommended by British 
Thyroid Association is described in Table 1.11 (Perros, Boelaert et al. 2014) 
 
Table 1.11 Recommended terminologies for Thyroid Cancer 
Procedure  Definition  
Hemi-
thyroidectomy 




Total lobectomy leaving behind only the smallest 
amount of thyroid tissue (significantly less than 1 g) 
to protect the recurrent laryngeal nerves. 
Near-total 
thyroidectomy  
Complete removal of one thyroid lobe (lobectomy) 
with a near-total lobectomy on the contralateral side 
or a bilateral near-total procedure. This should be 
clearly defined in the operation note. 
Total 
thyroidectomy 




1.3.1 Surgery for Papillary Thyroid Cancer 
The guidelines for the treatment of PTC from well renowned endocrine organisations 












BTA (2014) ATA (2009) NCCN (2008)  
Extent of 
Thyoidectomy  


















Age ≥ 45 








Age <15 or >45 














T ≤1 cm 
N0 
Other than the 
Above 

































AACE-American Association of Clinical Endocrinologists 
AAES- American Association of Endocrine Surgeons 
BTA- British Thyroid Association (Perros, Boelaert et al. 2014) 
ATA- American Thyroid Association (Cooper, Doherty et al. 2009) 
NCCN- National Comprehensive Cancer Network 
Ex- Extension of cancer beyond thyroid capsule 
N (+) - Metastatic Lymph node on imaging 
 
BTA recommends total thyroidectomy for large tumours or tumours of any size with 
additional risk factors. This has shown to be associated with fewer recurrences and 
better survival (Bilimoria, Bentrem et al. 2007; Pelizzo, Boschin et al. 2007). 
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According to ATA, patients with thyroid cancer >4 cm, or with gross extrathyroidal 
extension or clinically apparent metastatic disease to nodes or distant sites, the 
initial surgical procedure should include a near-total or total thyroidectomy (Haugen, 
Alexander et al. 2016).  
For patients with tumours 4 cm or smaller and no risk factors, hemi-thyroidectomy 
without radioiodine remnant ablation (RRA) is reported to have an equally 
favourable outcome to total thyroidectomy (Nixon, Ganly et al. 2012; Matsuzu, 
Sugino et al. 2014).  
 
1.3.2 Central Lymph Node Dissection 
Guidelines from renowned endocrine associations regarding central LN dissection 
are tabulated in Table 1.12.  
ATA recommendation is ‘therapeutic central-compartment (level VI) neck dissection 
for patients with clinically involved central or lateral neck lymph nodes’ (Cooper, 
Doherty et al. 2009). ‘pCLND (ipsilateral or bilateral) may be performed in patients 
with papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes, 
especially for advanced primary tumours (T3 or T4)’(Cooper, Doherty et al. 2009). 
The recommendation has ‘B’ and ‘C’ respectively which implies the strength is 
limited by the number, quality, or consistency of the individual studies or is based on 
expert opinion (Cooper, Doherty et al. 2009).  
 
British Thyroid Association (BTA) guidelines do not recommend prophylactic central 
neck LN dissection for patients without clinical or radiological evidence of lymph 
node involvement, who have all of the following characteristics: classical type PTC, 
<45 years, unifocal tumour, ≤4 cm, no extra-thyroidal extension on US (Perros, 
Boelaert et al. 2014) .  
The evidence is based on databases and retrospective cohort studies and hence not 
of the highest level (Costa, Giugliano et al. 2009; Moo, McGill et al. 2010; Moreno, 
Edeiken-Monroe et al. 2012; Barczynski, Konturek et al. 2013). For patients deemed 
to be high risk based on one or more of the following (adverse histological sub type, 
age ≥ 45 years, multifocal, tumours greater than 4 cm in diameter, extra-thyroidal 
54 
 
extension), the recommendation is ‘personalised Decision Making’. The level of 
evidence is described by BTA is ‘4,D’ which is again based on cohort studies. 
‘Personalised Decision making’ involves multidisciplinary team meeting, expert 
opinion and available expertise locally (Perros, Boelaert et al. 2014).    
Guidelines from the Japan Society of Thyroid Surgeons (JSTS) however recommend 
prophylactic central LND at initial surgery because reoperation for recurrence to this 
compartment may induce severe complications-‘recommendation rating= B’(Takami, 
Ito et al. 2011) 
 
 
1.3.3 Lateral Lymph Node Dissection 
ATA recommends therapeutic lateral LND for (Cooper, Doherty et al. 2009) biopsy 
proven metastatic lateral cervical lymphadenopathy. This recommendation has a ‘B’ 
rating according to ATA guidelines and relies on the detection of cervical LN on US.  
(Cooper, Doherty et al. 2009). As highlighted in our previous literature review, US has 
poor sensitivity and hence cannot be relied upon for staging PTC tumours (Mulla M 
2012).  
British Thyroid Association in its guidelines concludes that pLLND in patients without 
central LN metastases is not recommended (Perros, Boelaert et al. 2014). For 
patients with central LN metastases, the recommendation for pLLND is ‘personalised 
decision making’ (evidence Level ‘4D’) which is based on multidisciplinary team 
meeting, expert opinion and available expertise (Perros, Boelaert et al. 2014).  
Guidelines from the Japanese Society of Thyroid Surgeons (JSTS) regarding the role 
of prophylactic lateral LND remains undetermined. However JSTS guidelines 
recognises the significance of pLLND in reducing recurrences (Ito Y 2010).  
 
1.3.4 Treatment of Follicular Thyroid Carcinoma 
FNAC cannot distinguish follicular adenoma or benign hyperplastic nodules from 
carcinoma. Follicular cytology (Thy3) usually mandates at least a diagnostic hemi-
thyroidectomy (Perros, Boelaert et al. 2014). If definitive histology reveals a follicular 
adenoma or a hyperplastic nodule, no further treatment is required.  
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Patients with tumours ≤4 cm, in the absence of other adverse risk factors appear to 
have an excellent prognosis (Sugino, Kameyama et al. 2012; Goffredo, Cheung et al. 
2013). BTA recommends hemi-thyroidectomy for these patients (Perros, Boelaert et 
al. 2014).  
Patients with follicular tumours >4 cm appear to have worse prognosis (D'Avanzo, 
Treseler et al. 2004; Mete and Asa 2011) and should be treated with total 
thyroidectomy (Perros, Boelaert et al. 2014). 
Patients with tumours >1–≤4 cm and adverse risk factors (age >45 years, widely 
invasive, lymph node/distant metastases, angioinvasion) should be treated with total 
thyroidectomy (Perros, Boelaert et al. 2014) . 
 
1.3.5 Treatment of Hurthle Cell Carcinoma  
Recommendations from British Thyroid Association (BTA) on the surgical treatment 
of HCC are as follows (Perros, Boelaert et al. 2014) 
• In patients with tumour less than 1 cm hemi- thyroidectomy or total 
thyroidectomy is recommended. 
• For carcinomas > 1 cm, total thyroidectomy is recommended 
• Therapeutic lymph node dissection is advocated in patients with clinical or 
radiological evidence of lymph node involvement and confirmed metastasis. 
• Evidence for prophylactic neck dissection is unclear. 
 
1.3.6 Medullary Thyroid Carcinoma 
Medullary thyroid cancer (MTC) accounts for nearly 5%–10% of all thyroid cancers 
(Sippel, Kunnimalaiyaan et al. 2008). It is a malignancy of the parafollicular ‘C’ cells of 
the thyroid. The C cells originate from the embryonic neural crest, hence MTC’s 
often have the clinical and histological features of other neuro-endocrine tumours. 
The C cells secrete a variety of peptides and hormones with calcitonin being the 
most common. Serum calcitonin levels are elevated in patients with MTC and can be 
used to confirm the diagnosis as well as for follow-up of patients.  
Most medullary thyroid carcinomas are sporadic, however about 25 percent are 
familial and form part of the Multiple Endocrine Neoplasia type 2 (MEN2) syndrome. 
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Their clinical course varies from an extremely indolent tumour to an aggressive 
variant that is associated with a high mortality rate. 
  
Sporadic MTC’s- They form nearly 75% of all cases of the disease. The typical age of 
presentation is in the fourth and sixth decades of life (Leboulleux, Baudin et al. 
2004). The most common presentation is that of a solitary thyroid nodule which 
occurs in 75-95% of patients (Dottorini, Assi et al. 1996; Kebebew, Ituarte et al. 
2000). 
In most patients with MTC, metastasis has already occurred at the time of diagnosis.  
About 70% of patients have cervical metastases and 10% have distant metastases 
(Moley 2010). Central and lateral compartment lymph node metastases are present 
in 86% and 93% of patients with T4 tumours respectively (Machens, Hinze et al. 
2002). Nodal metastases are reported to be more common in patients with 
multifocal disease (Machens, Hauptmann et al. 2007). Site of distant metastases are 
often the liver, lung, bones and less commonly to the brain and skin.  
 
Hereditary or Familial MTC  
As previously mentioned majority of MTC’s are sporadic but about 20-25% are 
familial and form part of the MEN 2 syndrome (Multiple Endocrine Neoplasia). MEN2 
is sub-classified into two distinct syndromes namely MEN2A and MEN2B) each of 
which is transmitted in an autosomal dominant pattern and associated with MTC. 
MEN2A is more common accounting for about 75% cases (Sippel, Kunnimalaiyaan et 
al. 2008). MEN2A, is associated with MTC, pheochromocytoma, and primary 
parathyroid hyperplasia. These tumours are typically bilateral and multicentric, age 
of presentation is variable but it is usually in early adulthood. Pheochromocytomas 
are seen in up to 50% of cases and can be screened for using either plasma 
metanephrines or 24-hour urine collections for catecholamines and metanephrines 
(Sippel, Kunnimalaiyaan et al. 2008). Screening for hyperparathyroidism can be 
performed with serum calcium and parathyroid hormone levels. Some other variants 




In MEN2B, there is similar inherited predisposition to MTC and pheochromocytoma 
as MEN2A, but does not include hyperparathyroidism. The tumour develops at an 
earlier age and has an aggressive course than in MEN2A. A characteristic feature of 
MEN-2B is the development of diffuse ganglioneuromas of the lips, tongues, eyelids, 
and gastrointestinal tract. These patients have a characteristic appearance, including 
a Marfanoid habitus, everted eyelids, and thick lips (Sippel, Kunnimalaiyaan et al. 
2008). 
 
Treatment of Medullary Thyroid Carcinoma 
Unlike most other thyroid cancers, medullary thyroid cancer does not absorb RAI and 
therefore the best chance of curing a patient is completely removing the cancer at 
the first operation. 
A summary of recommendations provided by British Thyroid association 
recommendation (BTA) (Perros, Boelaert et al. 2014) is as follows- 
• Minimum of Total thyroidectomy and central LN dissection for established 
MTC. 
• Patients with clinical or radiologically involved lymph nodes in the lateral 
compartment, patients should undergo selective lateral neck dissection of 
levels IIa–Vb in addition to total thyroidectomy and central lymph node 
dissection. 
• Ipsilateral prophylactic lateral neck dissection is recommended in the 
presence of central compartment node metastases on the basis that the risk 
of lateral node involvement is at least 70%. 
• About 35% patients with central compartment node metastases will have 
contralateral lateral compartment node metastases (Machens, Hauptmann et 
al. 2008). Studies have shown that bilateral lateral neck dissection in patients 
will achieve biochemical cure in 50% of patients (Machens and Dralle 2010). 
Although this will reduce calcitonin levels, its impact on survival is less 
certain. Therefore, prophylactic bilateral lateral compartment node 




• Children with MEN2B should undergo prophylactic thyroidectomy preferably 
within the first 6 months but within the first year of life (Leboulleux, Travagli 
et al. 2002; Brauckhoff, Machens et al. 2014) 
• Children with MEN 2A should undergo thyroidectomy before the age of 5 
years (Rohmer, Vidal-Trecan et al. 2011)  
• Prophylactic lymph node dissection at the time of thyroidectomy should be 
considered in gene carriers based upon the basal calcitonin level.   
 
Routine adjuvant external beam radiotherapy EBRT should be considered only once 
optimal surgery has been performed and if there is significant risk of local recurrence 
(Wilson, Millar et al. 2004) 
 
1.3.7 Radioiodine Remnant ablation (RRA) for Differentiated Thyroid 
cancer 
Also known as RRA, it is used as an adjunct to near total or total thyroidectomy in  
differentiated thyroid cancer (Perros, Boelaert et al. 2014). Iodine is concentrated by 
differentiated thyroid cancers but not by poorly differentiated carcinoma, medullary 
carcinoma, lymphomas and anaplastic carcinomas (Carballo and Quiros 2012). Hence 
these cancers which do not concentrate iodine are not candidates for Radio-iodine 
treatment (Carballo and Quiros 2012). After surgery for Differentiated Thyroid 
Cancer (DTC), some 131I uptake is usually demonstrable in the thyroid bed. 131I-
induced destruction of this residual thyroid tissue is known as ‘radioiodine remnant 
ablation’ (RRA) (Perros, Boelaert et al. 2014).  
 
Mechanism of Radio- Iodine Treatment 
 
Radioiodine (RAI) is taken up and concentrated in thyroid follicular cells via a 
membrane called sodium-iodide transporter (Carballo and Quiros 2012) . Thyroid 
Stimulating Hormone (TSH) stimulates thyroid tissue and cancer cells to take up 
radioactive iodine. RAI therapy is most effective when circulating levels of TSH or 
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thyrotropin are high in blood. The most effective form of iodine isotopes used in the 
treatment for papillary thyroid cancer is I-131 (Silberstein 2012). 
 
Optimisation of patients for RRA 
 
-All patients should have undergone total thyroidectomy before administration of 
radio-iodine therapy. It has been shown that complete surgical removal of normal 
and pathologic thyroid tissue increases the efficacy of RAI treatment in destroying 
metastatic disease (Sakorafas, Sampanis et al. 2010). RAI treatment can be inefficient 
in tumours without radio-iodine uptake in 25-30% of cases (Jallon, Bonnet et al. 
2009).  
-Exogenous Iodine: Radio-iodine uptake is suppressed by increased endogenous 
stores or exogenous iodide. Exposure to iodinated intravenous contrast and 
treatment with drugs like amiodarone which is rich in iodine content may 
compromise the efficacy of radio-iodine (Perros, Boelaert et al. 2014). Generally, a 
low iodine diet two weeks prior to RRA is advised.  
 
1.3.8 TSH stimulation with recombinant human TSH (rhTSH) or Thyroid 
Hormone Withdrawal (THW)  
 
For ablative RAI treatment to be most effective, high TSH levels are required to 
maximise uptake by thyroid remnants or residual tumour cells (Reiners, Dietlein et 
al. 2008). This can be achieved by two different methods.  
TSH can be stimulated exogenously by injection of rhTSH. Recombinant human TSH 
is a synthetic drug that is used to provide TSH stimulation without withdrawal of 
thyroid hormone and the associated symptoms and morbidity (Carballo and Quiros 
2012). Alternatively, TSH can be stimulated endogenously by withholding thyroid 
hormone (T4) approximately 3 weeks after thyroidectomy (Serhal, Nasrallah et al. 
2004). This is termed as ‘Thyroid Hormone Withdrawal’ (THW). This can cause 
hypothyroidism and the symptoms associated with it. Randomised trials have shown 
that RAI therapy is equally effective after rhTSH or THW for selected patients with 
DTC (Mallick, Harmer et al. 2012; Schlumberger, Catargi et al. 2012).  
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Recombinant TSH is the recommended method of preparation for RRA in patients 
with T1 to T3 tumours with no lymph node or distant metastases (Perros, Boelaert et 
al. 2014). It is not currently used for patients with high risk of recurrence, or for the 
treatment of recurrent or metastatic DTC (Perros, Boelaert et al. 2014). 
 
1.3.9 Indications for RRA 
 
There is no clear evidence that all patients will benefit from RRA. In a significant 
group, the evidence is inadequate and conflicting. Therefore clear recommendation 
cannot be made (Perros, Boelaert et al. 2014) and are not available (Haugen 2004; 
Hackshaw, Harmer et al. 2007). For these reasons, RRA patients can be classified into 
three categories: (a) definite indications for RRA (b) uncertain indications for RRA (c) 
no indication for RRA as in Table 1.13. 
 
Table 1.13  Indications of RRA (Perros, Boelaert et al. 2014) 








Any one of the criteria 
below should be met 
 
• Tumour >4cm 
• Any tumour size with 
gross extra thyroidal 
extension 
• Distant metastases 
present 
 
All below criteria Should be met 
 
• Tumour <1cm unifocal or    
    multifocal 
• Classical papillary or follicular 
variant of papillary carcinoma, or 
follicular carcinoma 
• Minimally invasive without 
angioinvasion  
• No invasion of thyroid capsule 
(extra thyroidal extension) 
 
All other cases-  
May benefit from RRA 
 
• Large tumour size 
• Extra-thyroidal extension 
• Unfavourable cell type (tall cell, columnar or 
diffuse sclerosing papillary cancer, poorly 
differentiated elements) 
• Widely invasive histology 
• Multiple lymph node involvement, large size of 
involved lymph nodes, high ratio of positive to 






The benefits and side effects of RRA treatment is summarised in Table 1.14. 
 
Table 1.14 Advantages and Disadvantages of RRA (Perros, Boelaert et al. 2014) 
 
Advantages Disadvantages/Side effects 
 
- Eradication of all residual thyroid cells subsequent reduced 
risk of local and distant tumour recurrence (Hackshaw, 
Harmer et al. 2007) 
- Possible prolonged survival (Sawka, Thephamongkhol et al. 
2004) 
-Destruction of all thyroid tissue providing reassurance to 
patients 
- Increased sensitivity of Tg monitoring facilitating early 
detection of recurrent or metastatic disease (Mazzaferri 
1999) 
- Increased sensitivity of subsequent iodine scanning if 
required 
 
- Nausea  
- Radiation cystitis, gastritis, bleeding  
- Need to avoid pregnancy (6 months)        
or fathering a child (4 months)  
- Increased risk of miscarriage in the 
first year  




- Pulmonary fibrosis 
 Second malignancies 
 
 
RAI has shown to reduce the risk of local and distant metastases in high risk tumours 
(Sawka, Thephamongkhol et al. 2004). It’s role in low risk tumours however remains 
less convincing (Hay, McConahey et al. 2002). It has shown to effective in dealing 
with recurrences and undetected metastases (Mazzaferri 1997).  However, there is 
lack of firm evidence for the above and the treatment is not firmly established 
(Pacini, Schlumberger et al. 2005).  A systematic review by Sawka et. al failed to 
confirm the use of radioiodine ablation in decreasing recurrences and cause specific 
mortality (Sawka, Brierley et al. 2008). 
As is evident from Table 1.14, RAI is associated with significant side-effects ranging 
to neck pain and sialadenitis (Reiners, Dietlein et al. 2008) to serious and largely dose 
dependent complications including leukaemia and secondary solid tumours (Rubino, 





1.3.10 TSH suppression 
In patient with thyroid cancer after thyroidectomy, thyroid hormone replacement 
therapy is required. This is not only to replace endogenous thyroid hormone but it is 
generally thought to inhibit tumour growth indirectly by its negative feedback effects 
on pituitary Thyroid Stimulating Hormone (TSH) secretion (Cooper, Specker et al. 
1998). Thyroid hormone replacement is usually in the form of levothyroxine (T4). 
Usually a large T4 dose is required to suppress blood TSH levels below the normal 
range. This is called ‘TSH suppression’. 
 
Rationale and evidence for TSH suppression 
 
DTC’s express TSH receptor on the cell membrane and respond to TSH stimulation. 
This stimulation leads to increase in expression of several thyroid specific proteins 
namely thyroglobulin and sodium-iodine symporter, and increases rates of cell 
growth (Biondi and Cooper 2010). Hence suppression of TSH with high doses of T4 
hormone is used in thyroid cancer patients in an attempt to decrease the risk of 
recurrences (McGriff, Csako et al. 2002; Piccardo, Arecco et al. 2013).  
Evidence from many studies has shown that there are long term benefits from TSH 
suppression especially in high risk tumours.  In one study, TSH suppression was an 
independent predictor of disease progression in patients with stage III or IV PTC, but 
not in those with low-risk tumours (Jonklaas, Sarlis et al. 2006; Hovens, Stokkel et al. 
2007). 
Another study by Pujol et al. showed that thyroid cancer patients with TSH levels 
that were consistently low had an improved rate of relapse-free survival compared 
with those whose with higher levels (Pujol, Daures et al. 1996). Decreased 
recurrences and mortality after TSH suppression is evident only in patients with high-
risk differentiated thyroid cancers (Biondi and Cooper 2010). 
BTA guidelines recommend evaluation of response and risk of recurrence according 
to Dynamic risk Stratification 9-12 months after initial treatment (Perros, Boelaert et 
al. 2014). In patients with an incomplete response serum TSH should be suppressed 
below 0.1 mU/l indefinitely. In patients who have an indeterminate response, it is 
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recommended to maintain serum TSH concentrations between 0.1 and 0.5 mU/l. In 
patients with an excellent response to treatment for thyroid cancer, the serum TSH 
should be maintained in the low-normal range between 0.3-2 mU/l. 
The ATA recommends initial TSH suppression to below 0.1 mU/L for high and 
intermediate risk thyroid cancer patients, while maintenance of the TSH at or slightly 
below the lower limit of normal (0.1–0.5 mU/L) is considered appropriate for low-
risk patients (Haugen, Alexander et al. 2016).  
 
1.3.11 Thryoglobulin 
Thyroglobulin (Tg) is commonly used in the follow-up of patients with PTC. It is a 
glycoprotein produced only by normal or neoplastic thyroid follicular cells 
(Ibrahimpasic, Nixon et al. 2012). Detection of Tg post total thyroidectomy and LN 
dissection indicates the presence of persistent thyroid tissue or disease (Francis and 
Schlumberger 2008). Therefore, it is of importance when less than total 
thyroidectomy has been performed.  When proper total thyroidectomy and LN 
dissection is done, Tg level should be undetectable and hence any rise subsequently 




















Chapter 2  
Design and Aims of the Thesis
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There are two types of surgical approaches employed in the treatment of cervical 
Lymph node metastasis in PTC namely ‘prophylactic’ and ‘therapeutic’ cervical lymph 
node dissection. The aim of the thesis was to investigate the role of cervical Lymph 
Node Metastasis and their long-term outcomes in the context of the above 
mentioned surgical approaches.  
 
2.1 Primary Aims 
1. To determine the incidence of cervical lymph node metastases in Papillary Thyroid 
Carcinoma. 
2. To compare the long-term outcomes between prophylactic and therapeutic 
cervical lymph node dissection in PTC. 
 
2.2 Secondary Aim 
To establish if preoperative imaging reliably predicts nodal metastasis in the central 
and lateral compartment of the neck in papillary thyroid cancer.  
 
The study is divided into two parts- 
 
2.3 Part A 
Systematic reviews 
We conducted three systematic reviews as part of the thesis- 
1. Systematic review of Central Cervical LN metastases in PTC 
2. Systematic review of Lateral Cervical LN metastases in PTC 
3. Systematic review of Imaging of cervical LN metastases in PTC 
 
2.4 Part B 
Multicentre Retrospective Cohort Study 
This study covered a period of 9 years and data was collected from three major 
hospitals in London.  





Chapter 3  
Systematic Review of Central Cervical Lymph Nodes Dissection 
in Papillary Thyroid Cancer 
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3.1 Aims and Objectives 
 
1. To determine the extent of central cervical Lymph Node involvement in 
Papillary Thyroid cancer  
2. To compare the outcomes between prophylactic and therapeutic central 
cervical LN dissection in PTC. 
 
3.2 Inclusion and Exclusion Criteria  
The following inclusion and exclusion criteria were applied: 
Inclusion Criteria 
• All studies of patients with papillary thyroid cancer undergoing either 
prophylactic or therapeutic lymphadenectomy of the central cervical lymph 
nodes published over 40 years from 1970-2009. 
• Studies involving imaging modalities in the detection of central cervical LNs in 
PTC published over the last 10 years. 
Exclusion Criteria 
• All studies with less than 100 patients and/or less than 2 years follow up 
were excluded. 
Keywords:  
The following search terms were used always in combination with ‘Papillary thyroid 
cancer’ (PTC)- ‘therapeutic central lymph node dissection’, ‘prophylactic central 
lymph node dissection’ ‘Recurrence’, ‘death’, ‘recurrence’ and survival’, ‘radioiodine 
therapy’ and ‘radiotherapy’. 
 
3.3 Methods 
• An extensive search was conducted on the MEDLINE database via the 
Pubmed interface (http://www.ncbi.nlm.nih.gov/pubmed). ISI web of 




• The search covered a 40-year period from 1970 up to October 2009 with the 
combination of above mentioned search terms. The search was restricted to 
the presence of these key words in the title or abstract of the articles.  
• Preliminary search using these terms yielded 11,924 publications of which 
1402 were identified according to the inclusion and exclusion criteria.  
• Abstracts of all 1402 publications were further scrutinised for presence of 
relevant data. Out of these, 95 publications containing relevant data were 
read in full-text.  
• This process identified 23 studies appropriate for analysis based on the 
criteria set out above. All 23 publications were subjected to forward and 
backward quotation searches using the Thompson resource ‘ISI Web of 
Knowledge’ (http://apps.isiknowledge.com/). This identified three further 
studies which are included. Hence a total of 26 studies were included in the 
analysis. 
• Out of these 26 included studies, 21 provided data for central cervical lymph 
node dissection and 5 were imaging studies.  
• 21 studies providing data for central cervical lymph node dissection are as 
follows- (Wada N 2003; Shindo, Wu et al. 2006; Sywak M 2006; Lee YS 2007; 
Roh JL 2007; Davidson HC 2008; Low TH 2008; Palestini N 2008; Se Jun Choi, 
Kyoung-Ja Cho et al. 2008; Son YI 2008; Bonnet S 2009; Chung YS 2009; Costa, 
Giugliano et al. 2009; Koo, Choi et al. 2009; Mercante G 2009; Moo TA 2009; 
Perrino M 2009; Rosenbaum MA 2009; Sadowski BM 2009; Wada N 2009; 
Zuniga S 2009).  
• A standard proforma was used to extract data from the articles including 
details of the study population, type of surgical approach, imaging used to 
detect metastatic cervical LN, number of cervical lymph nodes positive on 
histology and any comparative results if available. All were retrospective 
cohort studies with no direct comparable data. There were no randomised 





• There were no studies comparing outcomes between prophylactic and 
therapeutic cervical LN dissection.  
 
  3.4 Statistical Methods 
 
For analysis, standard procedures were not used as there was no study with 
combined comparative data for prophylactic and therapeutic LN dissection. To 
simplify the results, we have used simple percentages. 
 
3.5 Results  
Literature search yielded 21 studies which provided data were included in this 
review. Data was available for 4188 patients from 21 studies for prophylactic and 
therapeutic central LND.  Fourteen studies provided results for only prophylactic 
central LND.  Four studies provided results for therapeutic central LND and in three 
studies results were available for both prophylactic and therapeutic central LND. 
Figure 3.1 shows a flow chart detailing the process of inclusion and exclusion of 


















Figure 3.1 Flow chart illustrating the process of inclusion and exclusion of studies 
71 
 
The baseline characteristics and methodology of the included studies for central cervical LN are shown in Table 3.1 
Table 3.1: Characteristics of included studies for central lymph nodes   
Study Year Study Design n 
Imaging used in 
Pre-operatively 
Type of Surgical 
Procedure 
Comments 
Shindo M 2006 Retrospective 100 None Prophylactic 
Study investigated incidence of positive LN in <45yrs vs >45yrs. 
Results showed 39% had positive LN in >45 yrs and 29% 
showed positive LN in 29%. 
Swyak M 2006 Retrospective 447 USS Prophylactic 
Patients with tumours >1cm included. Patients were divided in 
two groups; Group A-TT+ Ipsilateral CLND, Group B-TT alone 
Study compared postablative stimulate Tg level and number of 
radioiodine treatments. The authors found Tg levels lower in Group A 
compared to the other group. No difference was found in the  
complication rates.  
Lee YS 2007 Retrospective 103 USS Prophylactic 
Tumours <2 cms; USS negative for central LNM. Looked 
Serum Tg-concluded extent of CLND has no effect on  
Tg 
Low TH 2008 Retrospective 100 USS Prophylactic 
This study looked at Tg levels at 12 months postop. They concluded  
that LN metastases is associated with increased postoperative 
Tg levels.  
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Son YI 2008 Retrospective 114 USS Prophylactic 
Patients divided into two groups; Group A-Comprehensive CLND 
 (bilateral) and Group B (Unilateral). Complications and recurrence  
rates were compared at 2 years. Study found no difference in 
in recurrence rates between the two groups. 
Costa S 2009 
Retrospective 
Cohort 
244 USS Prophylactic LND 
Study divided into two groups 
Group A- TT+ pCLND 
Group B- TT  without CND 
Koo BK 2009 Prospective 111 USS+CT Prophylactic 
Prospective non-randomised trial. Clinically and 
radiologically node negative patients included. 
Zuniga S 2009 Historical Cohort 266 USS Prophylactic LND 
pCLND showed no advantage for neck  
recurrence 
Moo TAS 2009 Prospective 104 USS Prophylactic 
Investigated if ipsilateral CLND was sufficient in tumours <1cm. 
They concluded that in tumours <1cm Ipsilateral CLND maybe  
Sufficient. 
Choi JS 2008 2009 Retrospective 101 USS Prophylactic 
All patients had micro-carcinoma (<1cm). Patients divided into two  
groups- one with CLND and the other without CLND. There was no  
randomisation, the decision of CLND was based on surgeon’s and  
patient’s agreement. 37.5% with CLND had positive LN. 
Bonnet S 2009 Retrospective 115 USS Prophylactic 
This study looked at RAI ablations treatment in patients with  
tumours <2cms. Central LN metastasis was found in nearly 37% of 
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patients. These findings allowed selection of patients for RAI and 
modified the Indication for RAI in 30% of patients. 
Perrino M 2009 Retrospective 251 USS Prophylactic 
This study evaluated the predictor of outcomes after CLND in 
 Tumours <2 cms. They concluded that only lymph node metastases 
and extracapsular invasion were strongly associated with persistence  
 and recurrence. 
Mercante G 2009 Retrospective 445 USS Prophylactic 
All patients were micro-carcinoma (<1cm). Surgical treatment was 
 variable according to time period it was performed. CLNM were 
 present in 40% of patients. Recurrence was seen in 2.7%. 




This study included PTMC patients only. They looked at the incidence 
of skip metastases to lateral LN which was found to be 7.7%. The  
study recommended imaging to look for LN metastasis in all  
patients with PTMC.  







This study compared the complication rates between prophylactic 
and therapeutic CLND. No significant difference was found between 
the two groups. 






All included patients had PTMC. Patients were divided into two 
groups namely pCLND (Group A) and TT alone (Group B). They found  
no difference in terms of nodal recurrence between the two groups. 




CLND-Central Lymph Node Dissection; LLND-Lateral Lymph Node Dissection; PTMC-Papillary Thyroid MicroCarcinoma 





Disease Free Survival between patients undergoing prophylactic and 
therapeutic LND. They found DFS to be significantly better in pLND 
compared to tLND. 
Rosenbaum 2009 Retrospective 110 USS, Palpation Therapeutic 
Patients were divided into two groups-TT +CLND (Group A) and  
TT alone (Group B). The study concluded that recurrences were 
uncommon after CLND but had higher rates of complications. 
Roh JL 2007 Retrospective 155 Palpation Therapeutic 
The study Patients were divided in two groups- TT+CLND (Group A)  
and TT alone (Group B). They found that overall morbidity and  
hypocalcaemia was higher in the CLND group. 
Sadowski BM 2009 Retrospective 310 USS, Palpation Therapeutic 
Patients were divided into two groups- CLND and no CLND-46.7% of 
patients with CLND had positive LN. All recurrences occurred in  
patients without CLND.  
Davidson C 2008 Retrospective 183 USS, Palpation Therapeutic 
The study looked at incidence of LN metastases after different 
surgical procedures namely LN plucking, CLND and LLND. The 
highest rate of recurrence was found after LN plucking. 
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Table 3.2 shows results of prophylactic and therapeutic central lymph node 
dissection in patients with papillary thyroid cancer (Mulla and Schulte 2012).  
 
Table 3.2: Results of Central Lymph Node Dissection in Papillary Thyroid Carcinoma 
Study Patients 









   n  p LN + N p LN + 
Costa S 2009 244  126 59 na na 
Zuniga S 2009 266  136 112 na na 
Koo BK 2009 111  111 60 na na 
Lee YS 2007 103  103 39 na na 
Shindo M 
2006 
100  94 33 na na 
Moo TAS 2009  104  104 47 na na 
*Choi JS 2008  101  48 18 na na 
Son YI 2008 114  114 52 na na 
Bonnet S 2009 115  115 42 na na 
Perrino M 
2009 
251  92 39 na na 
Mercante G 
2009 
445  226 112 na na 
Low TH 2008 100  40 26 na na 
Swyak M 2006 447  56 21 na na 
Chung YS 2009 245  206 45 na na 
Palestini N 
2008 
305 Na 93 20 64 46 
Wada 2009 120 US, CT 47 30 73 72 
*Wada 2003 259 Palpation  235 143 24 23 




US-ultrasonography; CT-computerised tomography; pLN-histologically proven positive LN;  
Σ1-total number of patients included in the prophylactic LN dissection group;  
Σ2- total number of patients included in the therapeutic LN dissection group;  
Σ- grand total number of patients in both groups; na=Not available/applicable 
Total: 1244 (898 + 346)/4188 = 29.7%; prophylactic only: 898/3430 = 26.2%; therapeutic 
only: 346/1442 = 24%;  
*Papillary Microcarcinoma <1cm. 
 
A total of 4188 patients underwent therapeutic and/or prophylactic central LND, out 
of which 1244 had positive LN on histology (29.7%). Prophylactic central LND alone 
was performed in 1946 patients, of which 898 had positive central LN at surgery 
(46.1 %). A total of 1442 patients were assessed by various pre-operative methods 
for the presence of central LN.  Therapeutic central LN dissection was performed in 
438/1442 (30.4 %) patients guided by clinical examination and/or imaging.  
Of the 438 patients who underwent therapeutic central LND, positive central LN 
were found in 79% (346/438). Hence 24% (346/1442) of patients who were 





110 US, palpation na na 22 17 
Roh JL 2007 155 Palpation  na na 56 51 
Sadowski BM 
‘09 
310 US, Palpation na na 180 125 
Davidson C 
2008 
183 US, Palpation  na na 19 12 
Total (Σ2) 1442    438 346 
Total (Σ) 4188      





There were six studies in the review that provided results of primary tumours less 
than 2 cms. These include two studies with papillary microcarcinoma (Wada 2003 
and Choi 2008). Table 3.3 shows the results of CLND of these six studies. Out of 819 
patients with small primary tumours, LN metastases were found to be positive in 
48% of patients (393/819). 
 
Table 3.3 Results of Central Lymph Node Dissection (CLND) for papillary                 















In Table 3.4 are shown results of CLND according to primary tumour size. The results 
provided from three studies with patients classified as having tumours less than or 
greater than 1 cm. In tumours <1 cm, out of a total of 143 patients, 37 were found to 
have positive central lymph nodes (CLN) (26%). Out of 143 patients with tumours >1 












  n  p LN + N p LN + 
Mercante(2009) 445 226 112 na na 
Bonnet (2009) 115 115 42 na na 
Perrino (2009) 251 92 39 na na 
Choi (2008) 101 48 18 na na 
Lee(2007) 103 103 39 na na 
Wada(2003 259 235 143 24 23 
Total 1274 819 393 na na 
Percentages 393/1274=30.8% 393/819=48%  
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Two included studies provided results according to the T stages as shown in Table 
3.5. In patients classified as T1–T2, a total of 50 patients showed metastases out of 
88 (57%). In T3–T4 patients, 38 were positive out of a total of 88 (43%). 
 










The results of imaging for both central and lateral cervical lymph nodes are discussed 












Moo (2009) 104 45 16 29 
Koo (2009) 111 56 7 49 
Bonnett(2009) 115 42 14 28 
Total 330 143 37 106 








Shindo (2006) 100 33 23 10 
Costa (2009) 126 55 27 28 
Total 226 88 50 38 
Percentages   50/88=56.8% 38/88=43.2% 
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3.6 Discussion-Central Cervical Lymph Node Dissection 
 
3.6.1 Advantages of prophylactic Central LND 
There are several arguments in favour of pCLND. The high incidence of metastatic 
central cervical LN is one of the strong arguments. From our systematic review of 
central LND, the frequency of metastatic LN was 46.1% in prophylactic and 79% in 
the therapeutic approaches (Table 3.2). In tumours <2cms, which is T1 stage 
according to AJCC Cancer Staging (Cooper, Doherty et al. 2009), 48% patients 
showed metastases in CLN. According to ATA, 90% of patients with PTC will have 
microscopic metastatic disease in the cervical LN. (Cooper, Doherty et al. 2006). It is 
quite clear from these figures that central cervical metastases are found in a large 
proportion of patients with PTC. It is worth pointing out that even in T1 patients 
nearly half would be found to have metastatic LN if central LN are dissected 
prophylactically. Performing pCLND would therefore be crucial in complete staging 
and guide adjuvant radio-iodine treatment (Bonnet, Hartl et al. 2009). 
Another important argument is high loco-regional recurrence found in PTC. Loco-
regional recurrence rates in PTC are nearly 30% (Hay, Bergstralh et al. 1999; 
Leboulleux, Rubino et al. 2005). Several studies have shown that patients with initial 
nodal involvement have a higher rate of recurrence (Scheumann, Gimm et al. 1994; 
Hughes, Shaha et al. 1996; Davidson, Park et al. 2008; Soyluk, Selcukbiricik et al. 
2008). Leaving behind occult metastatic LN hence would predispose these patients 
to recurrences. An older study of 1,355 patients with 30 years of follow-up showed 
the likelihood of cancer death was increased by regional lymph-node metastases in 
patients without distant metastases (Mazzaferri and Jhiang 1994).  
Studies have shown that performing neck dissection on patients with lymph node 
metastases decreases the rate of regional recurrences and improves survival 
(Pereira, Jimeno et al. 2005; White, Gauger et al. 2007).  
Re-operative surgery to remove central LN is more challenging and puts the 
recurrent laryngeal nerve and parathyroid glands at increased risk (Shindo, Wu et al. 
2006; White and Doherty 2007). This higher incidence of recurrent laryngeal nerve 
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and hypo-parathyroidism after re-operative surgery is another reason to perform 
pCLND. (Pattou, Combemale et al. 1998; Kim, Mandel et al. 2004). 
 
3.6.2 Disadvantages of prophylactic Central LND 
Complications that can arise from central LN dissection are important factors which 
prevents against widespread adoption of prophylactic CLND (pCLND). Transient 
hypo-parathyroidism is a common complication associated with CLND (Chan, Lang et 
al. 2013), incidence of this has been reported anywhere between 14-44% (Mazzaferri 
EL 2009). Other complications include transient and permanent recurrent laryngeal 
nerve palsy. The incidence is 4-7.3% to 0-3.6% respectively.  
Many studies have shown no difference in the complication rates between pCLND 
and therapeutic CLND when performed by experienced surgeons (Roh, Park et al. 
2007; Xiao and Gao 2010). A recent systematic review showed a significant increase 
of transient hypocalcaemia in pCLND patients compared to those who underwent 
total thyroidectomy alone (Zhu, Zhong et al. 2013). However, the same review also 
found no significant difference in the incidence of permanent hypocalcaemia, 
temporary and permanent vocal cord palsy (Zhu, Zhong et al. 2013). 
 
Another argument against pCLND is that the presence of positive lymph nodes does 
not affect prognosis and survival in papillary thyroid carcinoma (Shaha, Shah et al. 
1996; Sato, Oyamatsu et al. 1998).  Some conclude that there is limited benefit for 
either disease recurrence or survival outcomes (Grebe and Hay 1996) and hence 
should be performed only in patients deemed high risk: larger tumours, extra-
thyroidal extension or aggressive histological subtypes (Iyer and Shaha 2011). 
Despite the above arguments, evidence from a large database of more than five 
thousand patients indicated that LN metastases has a negative impact on survival 
and a significantly higher mortality (Odds ratio=2.5; 95% CI, 1.6-4.1) (Lundgren, Hall 
et al. 2006). A literature review by White and colleagues concluded that addition of 
pCLND will add survival benefit to PTC patients (White, Gauger et al. 2007). pCLND 
has shown to reduce morbidity associated with potential reoperation, reduces the 
risk of central neck lymph node recurrence, provides more accurate information for 
staging, and facilitates postoperative radioactive iodine administration as well as 
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long term follow-up (Moo and Fahey ; Hughes, Shaha et al. 1996; Sawka, Brierley et 
al. 2008). A recent systematic review on the oncologic outcomes after pCLND 
showed that recurrence free survival may improve after pCLND although this was 
supported by low level evidence (Mamelle, Borget et al. 2015).  
A recent consensus report by the European Society of Endocrine Surgeons (ESES) 
analysed thirty studies and five meta-analyses on pCLND (Sancho, Lennard et al. 
2014).  It acknowledged the lack of randomized clinical trials on the subject, and the 
heterogeneity of study populations was the main limiting factors to draw clear 
conclusions. However, based on the available literature, they suggest that pCLND 
should be risk-stratified. Larger tumours (T3,T4), patients aged 45 years and older or 
15 years and younger, males, bilateral or multifocal tumours and patients with 
known involved lateral lymph nodes were all clear candidates for pCLND (Sancho, 
Lennard et al. 2014). On the other hand, very low risk patients, <45-year-old females 
with unilateral unifocal T1a tumours will probably not benefit from pCLND (Sancho, 
Lennard et al. 2014). They also recommend the procedure should be limited to 
surgeons who have the available expertise and experience.  
As is clear from the above discussion, pCLND is still an unresolved issue but it  is 
becoming a more common practice amongst surgeons (Moo and Fahey 2011).  
 
3.7 Limitations  
1. The review was not registered in accordance with PRISMA guidelines on databases 
such as PROSPERO. However, in hindsight it would have been better to have 
registered these on similar databases to ensure the consistency and quality of 
reporting. 
2. The quality of the included studies has not been assessed.  
3. There were no studies found comparing outcomes between prophylactic and 
therapeutic central cervical LN dissection. Hence outcomes comparing the two 






















Chapter 4 Systematic Review of Lateral Cervical Lymph Nodes 
















4.1 Aims and Objectives 
 
1. To determine the extent of lateral cervical Lymph Node involvement in 
Papillary Thyroid Carcinoma  
2. To compare the outcomes between prophylactic and therapeutic lateral 
cervical LN dissection in PTC. 
 
4.2 The following inclusion and exclusion criteria were applied to the review: 
Inclusion Criteria 
• All studies of patients with papillary thyroid cancer undergoing either 
prophylactic or therapeutic lymphadenectomy of the lateral cervical lymph 
nodes published over 41 years (1970-2011). 
• Studies involving imaging modalities in the detection of lateral cervical LNs in 
PTC published over the 12 year (1999-2011). 
Exclusion Criteria 
• All studies with less than 100 patients and/or less than 2 years follow up 
were excluded. 
Keywords:  
The following search terms were used always in combination with ‘Papillary thyroid 
cancer’, ‘lateral lymph node dissection’, ‘therapeutic lateral lymph node dissection’, 
‘prophylactic lateral lymph node dissection’, ‘recurrence’, ‘survival’, ‘Recurrence’, 
‘death’, ‘radioiodine therapy’ and ‘radiotherapy’.   
 
4.3 Methods 
• An extensive search was conducted on the MEDLINE database via the 
Pubmed interface (http://www.ncbi.nlm.nih.gov/pubmed). ISI web of 
knowledge was used for forward and backward quotation search 
(http://apps.isiknowledge.com/). 
• The search covered over a 41-year period (1970-2011). A combination of 
above mentioned search terms was used. The search was restricted to the 
presence of these key words in the title or abstract of the articles.  
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• Preliminary search using these terms yielded 11,924 publications of which 
1402 were identified according to the inclusion and exclusion criteria.  
• Abstracts of all 1402 publications were further scrutinised for presence of 
relevant data. Out of these, 95 publications containing relevant data were 
read in full-text.  
• This process identified 27 studies appropriate for analysis based on the 
criteria set out above. All 27 publications were subjected to forward and 
backward quotation searches using the Thompson resource ‘ISI Web of 
Knowledge’ (http://apps.isiknowledge.com/). This identified four further 
studies, which are included in the analysis. Hence a total of 31 studies were 
included in the analysis. 
• Out of these 31 included studies, 19 provided data for lateral cervical lymph 
node dissection and 12 were imaging studies.  
•  19 studies included in the analysis are as follows-(Patron, Bedfert et al. ; 
Attie 1988; Wada, Duh et al. 2003; Ito, Higashiyama et al. 2007; Roh, Park et 
al. 2007; Davidson, Park et al. 2008; Kim, Park et al. 2008; Low, Delbridge et 
al. 2008; Palestini, Borasi et al. 2008; Sugitani, Fujimoto et al. 2008; Wada, 
Masudo et al. 2008; Bonnet, Hartl et al. 2009; Choi, Kim et al. 2009; Chung, 
Kim et al. 2009; Kwak, Kim et al. 2009; Perrino, Vannucchi et al. 2009; Roh, 
Park et al. 2009; Sadowski, Snyder et al. 2009; Wada, Sugino et al. 2009). 
• A standard proforma was used to extract data from the articles including 
details of the study population, type of surgical approach, imaging used to 
detect metastatic cervical LN, number of cervical lymph nodes positive on 
histology and any comparative results if available. 
• There were no randomised controlled trials found in literature to enable a 
meta-analysis. All were retrospective cohort studies with no direct 
comparable data.  
• There were no studies comparing outcomes between prophylactic and 




4.4 Statistical Methods For analysis, the standard procedures were not used as 
there was no study with combined comparative data for prophylactic and 
therapeutic LN dissection. To simplify the results, we have used simple percentages. 
 
4.5 Results 
Nineteen studies provided data for lateral cervical LND and were included in this 
systematic review. Data was available for 5587 patients from 19 studies for 
prophylactic and therapeutic lateral LND.  All were cohort studies and no randomised 
controlled trials were found in the literature. Three studies provided results for 
prophylactic lateral LND alone. In fifteen studies the results were mixed for 
therapeutic and prophylactic lateral LND or therapeutic lateral LND alone. One study 
provided results for prophylactic lateral LND in 50% of the patient cohort; the 
remaining half underwent therapeutic LN dissection for which the results were 
unavailable (Attie 1988). Figure 4.1 shows flow chart illustrating the process of 








The baseline characteristics and methodology of the included studies for lateral cervical LN are shown in Table 4.1 
 
Table 4.1 Characteristics of included studies for lateral lymph nodes   
Study Year Study Design n 
Imaging used in 
Pre-operatively 
Type of Surgical 
Procedure 
Study Details 
Attie, J. N 1998 Retrospective 313 Palpation 
Prophylactic 
and Therapeutic 
Historical study-patient cohort included other types  
of thyroid cancers in addition to PTC(287/313). Nine 
patients with PTC died of the disease.  
Bonnett S 2009 Retrospective 115 USS Prophylactic 
Cohort included T1 tumours only (<2 cms). All  
patients underwent CLND in addition to pLLND. Only one 
patient had laryngeal palsy. pLND modification the 
indication for RAI in 30% of patients. 
Ito Y 2007 Retrospective 1231 USS Prophylactic 
The study investigated the incidence of lateral LN 
metastasis. All included patients were N0. The authors 
concluded that incidence of LLNM increased significantly 
with tumour size as did Lymph Node DFS. 
Patron V 2011 Retrospective 131 USS, Palpation Prophylactic 
This study looked at the pattern of lateral LNM in N0  
patients. Only tumours >1cm were included. They  
concluded occult LNM was most common in neck levels 
III, IIa, IV and Vb.  
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All included patients had PTMC. Patients were divided into 
two groups namely MRND (Group A) and TT alone  
(Group B). They found no difference in terms of nodal 
recurrence between the two groups; pLLND was not 
recommended. 
Wada 2008 Retrospective 231 USS, Palpation 
Prophylactic and 
therapeutic 
This study included patients with tumours >1cm. Clinical  
outcomes according to age and nodal status were 
evaluated. The study concluded that prognosis was 
worse in patients aged >45 and palpable LN. 




All included patients were <20 years old. The study  
compared at Disease Free Survival between patients 
undergoing prophylactic and therapeutic LND. They 
found DFS to be significantly better in pLND  compared 
to tLND. 
Roh JL 2007 Retrospective 155 Palpation Therapeutic 
The study Patients were divided in two groups- 
TT+CLND+LLND (Group A) and TT alone (Group B). They 
found that overall morbidity and hypocalcaemia was higher 
in the CLND group. Prophylactic LND was not  
recommended based on recurrences, pattern etc. 
Perrino M 2009 Retrospective 251 USS Therapeutic This study evaluated the predictor of outcomes after CLND 
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in Tumours <2 cms. All patients underwent pCLND and 
tLLND. They concluded that lymph node metastases and 
extracapsular invasion were strongly associated with 
persistence and recurrence. 
Sadowski 
BM 
2009 Retrospective 310 USS, Palpation Therapeutic 
Patients in this study had routine CLND and tLLND. 
They complications rates especially recurrent laryngeal  
nerve injury was low and the study concluded that CLND 
can be performed safely in experienced hands.  






This study compared the complication rates between 
prophylactic and therapeutic CLND. In addition, 
patients also had tLLND if lateral LN were ‘evident’. No 
significant difference was found in terms of permanent 
morbidity between the two groups. 
Davidson C 2008 Retrospective 183 USS, Palpation Therapeutic 
The study looked at incidence of LN metastases after 
different surgical procedures namely LN plucking, CLND 
and LLND. The highest rate of recurrence was found 
after LN plucking 




This study included PTMC patients only. They looked at 
the incidence of skip metastases to lateral LN which 
was found to be 7.7%. The study recommended imaging to 
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LLND look for LN metastasis in all patients with PTMC. 
Low TH 2008 Retrospective 100 USS Therapeutic 
This study looked at Tg levels at 12 months follow-up. 
Patients underwent pCLND and tLLND. They concluded  
that LN metastases is associated with increased  
postoperative Tg levels. 
Kwak JY 2009 Retrospective 671 USS Therapeutic 
Study included only PTMC patients. Only patients with  
USS confirmed LN underwent LND. The study evaluated  
USS features in PTMC that could predict lateral LNM. 
Sugitani I 2008 Prospective 361 USS Therapeutic 
PTMC patients were excluded from the study. This study 
evaluated the accuracy of USS in predicting LNM. They  
concluded CLND was sufficient if no lateral LN were 
found on USS.  
Choi  JS 2009 Retrospective 299 USS, CT Therapeutic 
Study compared diagnostic accuracy of USS versus CT in  
evaluating metastatic cervical LN. All patients underwent 
pCLND and tLLND as indicated. They concluded that high 
resolution USS was better than CT for lateral LNM and vice 
versa for central LNM. 
Roh JL 2009 Prospective 133 USS, CT 
Prophylactic 
and therapeutic 
Study evaluated use of USS in detecting cervical LNM. All 
patients had pre-operative USS and underwent CLND.  




Kim E 2008 Retrospective 165 USS, CT Therapeutic 
This study compared diagnostic accuracy of USS versus CT in  
evaluating metastatic cervical LN. Pre-operative USS and CT 
findings were compared to final histology results. The study 
concluded that combination of USS and CT was superior to 
USS alone in the detection of metastatic lateral cervical LN. 
 
CLND-Central Lymph Node Dissection 
LLND-Lateral Lymph Node Dissection 
LLNM-Lateral Lymph Node Metastasis 
PTMC-Papillary Thyroid MicroCarcinoma 
LND-Lymph Node Dissection 








Table 4.2 shows results of prophylactic and therapeutic lateral lymph node dissection 
in patients with papillary thyroid cancer.  
Table 4.2: Results of Lateral Lymph Node Dissection in Papillary Thyroid  












   n  p LN + n p LN + 
Bonnet S 2009ª 115  115 12 na na 
Ito Y 2007 1231  1231 790 na na 
Patron V 2011 140  131 26 na na 
Attie JN 1998° 313 Palpation  155 94 158 na 
Wada 2003* 259 Palpation  185 86 24 24 
Wada 2008 231 Palpation  201 151 30 na 
Wada 2009** 120 US, CT 30 18 na na  
Total (Σ1) 2409  2048 1177   
Roh JL 2007 155 Palpation  Na na 26 23 
Perrino M 2009 251 US, Palpation Na na 35 26 
Sadowski BM 2009 310 US, Palpation Na na 33 30 
Palestini N 2008 305 Na Na na 33 33 
Davidson C 2008 183 US, Palpation  Na na 73 61 
Low TH 2008 100 US, Palpation Na na 8 7 
Chung YS 2009 245 US, CT Na na 39 3 
Kwak JY 2009 671 US Na na 26 25 
Sugitani I 2008 361 US Na na 130 127 
Choi  JS 2009 299 US, CT Na na 53 29 
Roh JL 2009 133 US, CT Na na 34 34 
Kim E 2008 165 US, CT Na na 52 24 
Total (Σ2) 3178    566 446 
Total (Σ) 5587      
Percentage of 
positive Lymph node 
  1177/2048=57.5% 446/566= 78.8% 
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US-ultrasonography; CT-computerised tomography; pLN-patients with histologically proven positive 
LN; Σ1- total number of patients included in the prophylactic LN dissection group only; Σ2- total 
number of patients included in the therapeutic LN dissection group only; Σ, grand total number of 
patients in both groups;  na- not available. 
*Only T1 tumours were included; of these, 44% were micro-carcinomas, i.e., <1 cm. 
†Results of patients undergoing only prophylactic surgery (n = 155) available. 
‡PTMC: papillary thyroid micro carcinoma. The remaining 50 patients underwent prophylactic central 
LN dissection 
§Data from children. 
 
Total of 5587 patients underwent therapeutic and/or prophylactic lateral LND, out of 
which 1,623 had positive LNs on histology (29.1%). Prophylactic lateral LND alone 
was performed in 1447 patients, of which 828 had positive lateral LN at surgery 
(57.2%). In total, 2048 patients underwent prophylactic lateral LND out of which 
1177 were found to have metastatic positive lateral LN on histology (57.5%).  
In the therapeutic category, a total of 4101 patients were assessed by various pre-
operative methods for the presence of lateral LN. From the available data, 
therapeutic lateral LN dissection was performed in 566/3437 (16.5%) patients guided 
by clinical examination and/or imaging. Of these 566 patients, positive lateral LN 
were found in 446 (78.8%). Table 4.3 shows results of prophylactic lateral LN 
metastases depending on stage of the tumour. The percentage of lateral LN 














Table 4.3 T stage-dependent frequency of lateral lymph node (LN) metastases detected by 













number of patients 
<1  53/131 (40·5%) T1 261/530 (49·2%) 
1.1-2.0 208/399 (52·1%) T2 
401/553 (72·5%) 2.1-3.0 257/368 (69·8%) T2 
3.1-4.0 144/185 (77·8%) T2 
>4.1 128/148 (86·5%) T3+T4 128/148 (86·5%) 
Total 790/1231 (64·2) T1-T4 790/1231 (64·2%) 
 
 
4.6 Discussion-Lateral cervical LN dissection 
The treatment of lateral LN metastases is the most contentious area in the 
management of PTC. For decades, there has been considerable controversy 
regarding the type of surgical approach and the extent of lateral cervical lymph node 
dissection in PTC. One of the main reasons for this controversy is the lack of 
conclusive data which will provide us with useful information to formulate treatment 
plans.  
 
The site of metastases to cervical LN varies according to studies. Some authors 
report ipsi-lateral central neck to be the most common site of metastases. (Qubain, 
Nakano et al. 2002; Roh, Park et al. 2007). The risk is reported to be greatest for 
lateral LN of levels II, III, and IV (Wada, Duh et al. 2003). Tumours arising from the 
upper pole often spread to the ipsi-lateral lateral compartment whereas those 
arising from the mid and lower pole favour the central compartment (Park, Lee et al. 
2012; Zhang, Wei et al. 2012). This pattern of metastatic LN involvement can be 
attributed to the lymph drainage of the thyroid gland, which follows its venous 
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system. The frequency of skip metastases has been reported between 11.1%- 37.5% 
(Lee, Shin et al. 2014).  
The frequency of metastatic LN found in the lateral compartment varies. In our 
systematic review, the frequency of metastatic LN in the lateral compartment was 
found to be 57.5% where prophylactic LND was performed. One study (Ito, 
Higashiyama et al. 2007) provided the results according to T stage; they found the 
incidence of metastatic lateral LN to be 40% even in T1 tumours. From our own data, 
metastatic lateral LN were found to be positive in 70% of patients who had 
prophylactic LND which confirms the finding from published work.  
 
This high percentage of lateral metastatic LN found on prophylactic LND exposes 
significant pitfalls in the staging and subsequent management of these patients. 
Leaving behind these metastatic LN will lead to gross under-staging in these patients. 
Survival in different stages of PTC varies considerably according to the AJCC cancer 
staging (Edge SB 2010). Stage I and II have excellent prognosis but the survival drops 
to as low as 50% in stage IV. The staging progresses from I to III in the presence of LN 
metastases except in women <45 years of age who remain stage I. Under-staging of 
these patients will have a negative impact on their long-term outcomes and survival 
(Mulla and Schulte 2012).  
 
Studies have shown that patients with clinically proven metastases to the lateral 
compartment are more likely to have recurrences and have shorter disease free 
survival (Ito Y 2010; de Meer, Dauwan et al. 2012). Clinically proven cervical LN 
metastasis at the time of initial surgery has been shown to be an independent risk 
factor of tumour recurrence (Ito Y 2010; Bozec, Dassonville et al. 2011). A recent 
study of over 800 cases of PTC found that N1 patients treated with only TT and RAI 
had about 60% a risk of persistent disease (Guy, Hirsch et al. 2014). From our own 
cohort, there were no recurrences in patients who had prophylactic LND; whereas 
there were 9 recurrences in those with therapeutic LND.  
 
Loco-regional recurrent disease in PTC can vary anywhere between 8-23% (Kwang-
Min Kim 2012) and about 75% of these local recurrences occur in the cervical lymph 
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nodes (Hong SJ 2001). Although the majority of the recurrences happen in the first 
ten years after surgery, about 20% of these can happen between 10-20 years 
(Grogan, Kaplan et al. 2013). It has been reported that 10% of patients with local 
recurrences and 50% with distant recurrence will die of the disease (Mazzaferri and 
Jhiang 1994). Recurrences in the lateral cervical compartment are twice as common 
as the central compartment (Kruijff, Petersen et al. 2013).  Patients with clinically 
proven metastases to the lateral compartment are more likely to develop 
recurrences and have shorter disease free survival (Ito Y 2010; de Meer, Dauwan et 
al. 2012). Also presence of central metastases has shown to be an independent 
prognostic factor for lateral node recurrence disease (Barczynski, Konturek et al. 
2013). Advanced age, male sex, cervical metastasis and tumour size are the most 
important factors for higher recurrence (Ito, Higashiyama et al. 2007; Kim, Park et 
al. 2012).  
 
4.6.1 Disadvantages of prophylactic Lateral LND 
Complications that can arise from lateral cervical LND is one of the main arguments 
against adopting prophylactic LND. Minor chyle leak occurs in the region of 2.3%. 
Thoracic duct injury needing re-operation for repair is low, reported to be around 
0.6%. (Ito, Higashiyama et al. 2007; Ducoudray, Tresallet et al. 2013). The incidence 
of phrenic nerve injury, facial nerve paralysis, accessory nerve paralysis and Horner 
syndrome is also low in the range between 0.2% and 0.3% (Simon, Goretzki et al. 
1996; Ito, Miyauchi et al. 2007).  
Another source of controversy against the rationale for prophylactic LND is the 
uncertainty of the long-term outcomes from microscopic lateral LN metastases.  
(Lundgren, Hall et al. 2006; Bardet, Malville et al. 2008).  There are no clinical 
predictive factors for LN recurrences and the role of imaging in detecting these 
metastasis is limited. The above argument is flawed on two levels. Firstly, the lack of 
high level of evidence notably from randomised controlled trials makes it impossible 
to draw definitive conclusions on survival and outcomes. The available data is from 
cohort studies which are mostly retrospective hence rendering results open to 
debate. Secondly PTC being a slow growing tumour, recurrence and not survival is 
considered to the outcome of interest in PTC (Sakorafas, Sampanis et al. 2010).  
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4.6.2 Advantages of prophylactic Lateral LND 
 
There are several advantages of prophylactic LLND. It reduces the risk of recurrences 
in the cervical LN hence reducing the morbidity associated with re-operations (Ito, 
Kudo et al. 2012). About 10% of patients with local recurrence and 50% of those with 
distant metastasis will die of the disease (Mazzaferri and Jhiang 1994). Reoperations 
may be associated with high complication rates, such as injury to the recurrent 
laryngeal and spinal accessory nerve, hypoparathyroidism, and unsightly surgical 
scars (Esnaola, Cantor et al. 2001). For these mentioned reasons recurrence and not 
survival is considered to the outcome of interest in PTC (Sakorafas, Sampanis et al. 
2010). 
 pCLND provides more accurate information for staging more than half of patients 
with positive central LN who will have metastatic lateral LN. Imaging methods 
namely Ultrasonography and Computerised Tomography do not have the required 
sensitivity and specificity to detect metastatic cervical LN (Hartl, Leboulleux et al. 
2012). Hence performing pLLND remains the most reliable method of accurately 
staging patients with PTC (Hartl, Leboulleux et al. 2012). 
Re-operations in the cervical compartments are usually performed for recurrences 
and persistent disease. This is technically challenging and is associated with 
increased incidence of recurrent laryngeal nerve injury, persistent hypo-
parathyroidism, spinal accessory nerve injury, thoracic duct injury and unsightly 
scars. (Shindo, Wu et al. 2006; White and Doherty 2007; Sakorafas, Sampanis et al. 
2010).   
There are several studies which recommend prophylactic (Simon, Goretzki et al. 
1996; Lundgren, Hall et al. 2006) lateral LND and have shown improved disease free 
survival (DFS) particularly in older male patients with larger tumours (Ito, 
Higashiyama et al. 2007). Studies have shown that prophylactic LND reduces the 
chances of recurrences and re-operations in both central and lateral compartment 
(Ito Y 2010; Popadich, Levin et al. 2011). 
A recent in-depth review on surgical management of metastatic lateral LN 
recommends prophylactic lateral LND in tumours arising from upper pole, extensive 
ipsi-lateral or bilateral involvement of central compartment (Dralle and Machens 
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2013). This was based on the observation that tumours of the upper thyroid pole 
skip the central compartment spreading directly to the superior lateral nodes (Park, 
Lee et al. 2012; Zhang, Wei et al. 2012).  
The complications and morbidity rates quoted against pLLND are low in experienced 
hands and can be tolerated in view of the benefit achieved by the operation 
(Harness, Fung et al. 1986; Attie 1988; Ducoudray, Tresallet et al. 2013). 
The case to limit cervical LND to therapeutic as opposed to prophylactic is not 
evidence based. The evidence in support of prophylactic LN dissection is provided by 
many studies especially in high risk groups namely men, multi-focal tumour and 
extra-thyroidal tumour extension (So YK 2010), in which they have been shown to 
improve disease free survival (Ito, Higashiyama et al. 2007). Most clinicians agree 
that prophylactic LND allows for accurate staging of the disease that may guide 
subsequent treatment and follow-up (Pacini, Schlumberger et al. 2006). 
 
4.7 Limitations of the review 
1. The review was not registered in accordance with PRISMA guidelines on databases 
such as PROSPERO. In hindsight we would have preferred to have this registered on 
similar databases to ensure the consistency and quality of reporting. 
2. The quality of the included studies has not been assessed.  
3. There were no studies found comparing outcomes between prophylactic and 
therapeutic lateral cervical LN dissection. Hence outcomes comparing the two 













Chapter 5  
Systematic Review of Imaging of Metastatic Cervical Lymph 
Nodes metastases in Papillary Thyroid Cancer 
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5.1 Aims and Objectives 
Primary Objectives 
1. To understand if the commonly reported ‘sensitivity’ of imaging techniques is 
based on factual evidence. 
Secondary Objective 
1. To determine the diagnostic accuracy of USS and CT in detecting metastatic 
cervical LN. 
2. To determine the usefulness of other imaging modalities namely MRI, 18-FDG 
PET/CT in detecting metastatic cervical LN. 
 
5.2 Inclusion/Exclusion Criteria 
 
The following inclusion criteria were used for this systematic review. 
• Studies involving imaging modalities in detection of cervical lymph nodes in 
Papillary Thyroid Cancer published over a 17-year period (1995-2011) 
• All studies had to be published in English. 
 
Keywords 
The following search terms were used always with combination with ‘papillary 
thyroid cancer’ (PTC)- ‘LN dissection’, ‘sensitivity’, ‘specificity’, ‘therapeutic LN 
dissection, ‘Ultrasound’(USS), ‘Computerised Tomography’ (CT), Magnetic Resonance 
Imaging’ (MRI) and ‘18FDG PET–CT’. The search was restricted to the presence of 
one or more of these key words in the title or abstract of the articles. 
 
5.3 Methods 
• An extensive search was conducted on the MEDLINE database via the 
Pubmed interface (http://www.ncbi.nlm.nih.gov/pubmed). ISI web of 




• The search covered a period of 17 years. A combination of above mentioned 
search terms was used. The search was restricted to the presence of these 
key words in the title or abstract of the articles.  
• Preliminary search using these terms yielded 1129. Abstracts of all 1129 
publications were scrutinised for presence of relevant data. Out of these, 32 
publications containing relevant data were identified. 
• These 32 publications were read in full text and scrutinised for the presence 
of relevant data. This process identified 28 studies appropriate for analysis 
based on the criteria set out above. 
• Sixteen studies looked at sensitivity of USS, eight studies provided data for CT 
scan, one study involved MRI (31) and three studies provided data for 18FDG 
PET–CT  
• A standard proforma was used to extract data from the articles including 
details of the study population, number of LN detected by imaging, site of 
metastatic LN detected, percentage of positive LN on histology, sensitivity, 
specificity, positive predictive value and negative predictive value.  
• There were no randomised controlled trials found in literature to enable a 
meta-analysis. 
• The included studies are as follows- 
• 16 studies looked at sensitivity of US (Lee, Kawata et al. ; Yoon, Kim et al. ; 
Shimamoto, Satake et al. 1998; Lee, Jin et al. 2001; Kessler, Rappaport et al. 
2003; Torlontano, Attard et al. 2004; Ito, Tomoda et al. 2005; Ito, Tomoda et 
al. 2006; Jeong, Baek et al. 2006; Stulak, Grant et al. 2006; Gonzalez, Cruz et 
al. 2007; Ahn, Lee et al. 2008; Kim, Park et al. 2008; Sugitani, Fujimoto et al. 
2008; Choi, Kim et al. 2009; Roh, Park et al. 2009).   
• 8 studies provided data for CT (Yoon, Kim et al. ; Lee, Jin et al. 2001; Jeong, 
Baek et al. 2006; Ahn, Lee et al. 2008; Kim, Park et al. 2008; Soler, Hamilton 
et al. 2008; Choi, Kim et al. 2009; Lee, Kang et al. 2009). 
• One study involved MRI(Gross, Weissman et al. 2001) and 3 studies provided 
data for 18 FDG PET-CT(Yeo, Chung et al. 2001; Jeong, Baek et al. 2006; Lee, 
Kang et al. 2009). 
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5.4 Statistical Methods  






The type of surgical procedure varied between studies. Some studies had prophylactic whilst others had therapeutic LND. The study details 
and validity of included studies and the validity are shown in Tables 5.1 and 5.2. 
  











28 To determine the ability of MRI imaging to detect the presence 
of metastatic thyroid cancer in cervical LN 
NA NA NA NA a b b a Invalid 
Ito Y 2006 600 Investigate the clinical significance of LN in the central 
compartment  
27 339 3 231 b b b b Valid 
Sugitani I 
2008 
231 To prospectively analyse the outcomes of selective LND to 
determine when prophylactic lateral neck dissection is advisable 
40 86 9 96 a b b a Invalid 
Roh   JL 
2009C 
133 Evaluation of preoperative US in detecting cervical LN 
metastases in PTC 
NA NA NA NA b b b b Valid 
Choi JS 
2009 
299 To compare the diagnostic accuracy of US, CT and combined US 
and CT 
NA NA NA NA b b b b Valid 
104 
 
Kim E 2008 165 Determine the diagnostic accuracies of US, CT and combine US 
and CT 
20 75 6 32 a b b a Invalid 
Ahn JE 
2008 
9 Investigate the diagnostic ability of CT and US of cervical LN in 
thyroid cancer 
NA NA  NA NA a b b a Invalid 
Choi YJ 
2010 
589 To evaluate the diagnostic accuracy of preoperative US and CT 
of the neck 
NA NA NA NA a b b a Invalid 
Soler ZM 
2008 
102 Investigate the ability of CT to detect subclinical nodal disease in 
PTC. 
NA NA NA NA a b b a Invalid 
Central and Lateral 
Kessler A 
2003 
63 The usefulness of US in diagnosing cervical LNM in PTC was 
investigated 
14 43 0 6 a b b a Invalid 
Shimamoto 
K 1998 
77 To evaluate the usefulness of US for preoperative staging of PTC NA NA NA NA b b NA NA Invalid 
Torlontano 
M 2004 
456 Determine the sensitivity of neck US to detect LN metastases 38 NA NA 418 a b b a Invalid 
Lee DH 
2009 
11 If PET-CT is more accurate than CT for detecting metastatic 
cervical LN in PTC 
21 7 1 7 a b b a Invalid 
Yeo JS 
2001C 
22 Evaluate whether FDG-PET is feasible as a pre surgical evaluation 
modality for I-131 scan-negative thyroid carcinoma patients 
45 24 5 11 a b b a Invalid 
Gonzalez 60 To determine the frequency of occult macroscopic metastasis 11 47 1 1 a b b a Invalid 
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HE 2007 detected by preoperative US 
Stulak JM 
2006 
551 Preoperative US will increase detection and assessment of the 
extent of LNM in PTC 
NA NA NA NA a b b a Invalid 
Sen-Sensitivity; Spec-specificity; PPV-positive predictive value; NPV, negative predictive value 
TP-true positives; TN- true negatives; FP-false positives; FN-false negatives; NA-Not available/applicable 
a incorrectly calculated 
b correctly calculated 
c figures available by levels, no overall figures 
 










Investigate the diagnostic ability of CT and US of cervical LN in 
thyroid cancer 
NA NA NA NA a b b a Invalid 
Kim E 2008 165 
Determine the diagnostic accuracies of US, CT and combined US 
and CT 
20 75 6 32 a b b a Invalid 




To prospectively analyse the outcomes of selective LND to 
determine when prophylactic lateral neck dissection is advisable 
127 0 3 0 a b b a Invalid 
Roh JL 34 Evaluation of preoperative US in detecting cervical metastases in NA NA NA NA NA NA NA NA Invalid 
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To evaluate the diagnostic accuracy of preoperative US and CT of 
the neck 
NA NA NA NA a b b a Invalid 




To evaluate the most accurate criteria using US and CT in 
predicting lateral LN in PTC  




Investigate the ability of CT to detect subclinical nodal disease in 
PTC.  




To compare the diagnostic accuracy of US with that of CT in 
patients with PTC  
NA NA NA NA a b b a Invalid 
Sen-Sensitivity; Spec-specificity; PPV-positive predictive value; NPV, negative predictive value;  
TP-true positives; TN- true negatives; FP-false positives; FN-false negatives: NA-Not available/applicable 
a incorrectly calculated; b correctly calculated 
c figures available by levels, no overall figures
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5.5.1 USS (Table 5.3): For central LN, there were seven studies which provided the 
data (Mulla and Schulte 2012). Out of these, only 4 studies calculated sensitivity and 
NPV correctly.  The mean sensitivity and NPV of these 4 studies was 38.4% and 
60.9% respectively.  
11 studies providing data for lateral LN detection by US were included. Of these only 
one (Ito, Tomoda et al. 2005) was accurate in their calculation of sensitivity and NPV. 
The sensitivity and NPV for this study were 27.2% and 43%, respectively. Five studies 
provided clustered results for both central and lateral cervical LN detection, out of 

























Table 5.3 Ultrasonography in detection of cervical LN in PTC (Mulla and Schulte 
2012)  
 









Ito Y 2006 600 10.5 99.1 90 59.5 
Sugitani I 2008 231 29 91 82 47 
Roh JL 2009 133 61 93 92 63 
Kim E 2008 165 (38) 93 77 (70) 
Ahn JE, 2008 37 (55) 69 77 (44) 
Choi JS 2009 299 53 80 61 74 
Choi JY 2010 589 (47.2) 94.8 90.4 (63.5) 
Lateral 
Ito Y 2005 560 27.2 96.5 93.3 43 
Jeong HS 2006 26 (41.3) 97.4 73.1 (90.6) 
Stulak JM 2006 551 (83.5) 97.7 88.8 NA 
Sugitani I 2008    361 NA NA 98  NA 
Roh JL 2009 133 NA NA NA NA 
Kim E 2008 165 (64) 92 83 (82) 
Ahn JE 2008 37 (65) 82 86 (59) 
Choi JS 2009 299 (93.9) 25 93.9 (25) 
Choi JY 2010 589 (69.1) 94.8 57.6 (96.8) 
†Lee K 2010 70 (78.3) 98.7 99.5 (58.2) 
Yoon JH 2011 113 (74.3) 82.7 85.3 (70.5) 
Combined Central and Lateral 
Shimamoto K, 1998 77 36.7 89.3 NA NA 
Kessler A  2003 63 (70) 100 100 (87.6) 
Torlontano M, 2004 456 (100) 100 NA NA 
*Stulak JM 2006 219 (90.4) 78.9 93.9 NA 
Gonzalez HE 2007 60 (92) 98 92 (98) 
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Figures in brackets indicate erroneous calculations; *Re-operated group of patients; †Unclear if all LN were dissected;  
NA-not available/applicable 
 
5.5.2 CT (Table 5.4): Eight studies provided data on CT scan for detecting cervical LN. 
For central LN, five provided data out of which in only one (Choi, Kim et al. 2009) the 
calculations were correct. The sensitivity and NPV in this study was 67% and 80% 
respectively.  
 
Table 5.4 CT in the detection of cervical LN metastases in PTC (Mulla and Schulte 
2012) 











165 (50) 91 79 (74) 
Soler ZM 2008 102 (58) 72 72 (58) 
Ahn JE 2008 37 (74) 44 72 (47) 
Choi JS 2009 299 67 79 65 80 
Choi JY 
2010 




26 (42.3) 96.6 57.9 (93.8) 
Kim E 
2008 
165 (74) 95 89 (86) 
Soler ZM 2008 102 (50) 71 50 (63) 
Ahn JE 
2008 
37 (78) 78 86 (68) 
Choi JS 2009 299 (81.7) 100 100 (30.8) 
Choi JY 
2010 





113 (68.6) 78.8 81.4 (65.1) 
Combined Central and Lateral LN 
Lee DH 
2009 
11 (75) 87.5 95.9 (50) 
 
Figures in brackets indicate erroneous calculations 
  
Out of the seven studies included for lateral LN, none calculated the sensitivity and 
NPV correctly. There was one study with combined results for both central and 
lateral LN which again calculated inaccurately. 
5.5.3 MRI (Table 5.5): We found one study by Gross N. D et. al (Gross, Weissman et 
al. 2001) in literature providing data for use of Magnetic Resonance Imaging in 
detection of cervical LN which again failed to calculate it in a correct manner.  
5.5.4 18 FDG PET-CT (Table 5.5): Three studies provided results, one for lateral LN 



































27 (50) 97 65 (94.6) 
Combined Central and Lateral 
*Yeo JS 
2001 
22 (80) 83 90 (69) 
*Lee DH 
2009 




105 (95) 51 84 (78) 
Legend: Figures in brackets indicate erroneous calculations 
 
5.6 Discussion 
In any cancer management, it is crucial to have accurate staging as it impacts on the 
treatment strategy and hence on long-term outcomes and survival. Imaging 
modalities are integral part of this initial assessment and staging. Accurate diagnostic 
evaluation can often lead to stage migration from a lower to higher stage. Stage 
migration will be reflected in the overall cancer specific survival rates (Chan, Lang et 
al. 2013). The importance of a thorough preoperative evaluation in PTC and 
subsequent neck dissection to an appropriate extent during initial surgery has been 
emphasized in many studies (Chow, Law et al. 2003; Mazzaferri 2009).  As previously 
mentioned, cervical lymph node status at presentation affects long term outcomes 
(Lundgren, Hall et al. 2006). 
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In our systematic review, we assessed the ‘usefulness’ and ‘diagnostic accuracy’ of 
these imaging modalities. There are four parameters namely sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV), which define the 
diagnostic accuracy of a test. Of these parameters sensitivity and NPV are important 
as these represent those cases ‘NOT’ missed by the test (Mulla and Schulte 2012). 
For any imaging modality to be widely used for cancer staging, it would be expected 
to score high on all the four parameters. A false high sensitivity or negative 
predictive value of the tests employed would lead to under-staging. 
Sensitivity is the ‘proportion of true positives that are correctly identified by the 
test’(Altman and Bland 1994). Put in plain language, it is the ability of a test to 
identify those patients with the disease (Lalkhen A.G 2008), defined by the formula 
TP/TP+FN (TP-True positives; FN- False negatives). 
‘NPV’ is defined as the ‘proportion of subjects with a negative test result who are 
correctly diagnosed’(Altman and Bland 1994). In other words it is the likelihood of a 
patient not having the disease when the test result is negative (Lalkhen A.G 2008) 
and is defined by the formula TN/TN+FN (TN- True Negatives). 
For calculation of sensitivity and NPV, ‘False negatives’ (FN) values are required as is 
evident from the above formulae. The only practical method to obtain FN values is to 
dissect all cervical LN during surgery irrespective of image findings followed by 
comparison of histology results to those detected by pre-operative imaging. This 
alone will ascertain that all ‘FN’ cases are included. This can only be achieved by 
performing prophylactic lymph node dissection alone.  
From our systematic review on imaging, it is evident that out of the 16 studies 
providing values for sensitivity and NPV of US, only 6 studies calculated these values 
accurately leaving 10 studies with either incomplete or inaccurate data (Table 5.3). 
Results from studies involving CT, only one (Choi JS 2009) out of 8 studies provided 
accurate results for sensitivity and NPV. The remaining 7 studies provide incorrect 
results (Table 7.4). The same applies to 18 FDG PET-CT and MR studies; all 4 included 
calculated the values incorrectly (Table 7.5).  In summary, only 7 out of 28 imaging 
studies included have performed the calculations correctly leaving with 21 studies 
with incorrect calculations. In all the studies, which did not calculate the sensitivity 
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and NPV accurately, patients had therapeutic LND, hence ‘FN’ cases could not have 
been obtained.  
When correct scientific methodology was applied, the mean sensitivity and NPV of 
US was 36.2% and 57.3%, respectively. The only study, which provided correct 
results for CT had a sensitivity of 67% and NPV of 80% for central compartment only 
(Choi, Kim et al. 2009). 
The results from our review clearly shows that US and CT are not ideal imaging for 
the detection metastatic cervical LN. The discrepancies in calculating reflect a 
misunderstandings or simply incorrect definitions of the terms ‘sensitivity’ and ‘NPV’ 
in the context of imaging cervical LN in PTC.  
Ultrasound is operator dependent and hence individual results may be better than 
what has been published in literature. There are no set diagnostic criteria for 
detecting metastatic cervical LN although there are suspicious features as described 
previously. This adds to the problem of subjectivity in detecting suspicious LN even 
further. However, such operator dependency puts obvious limitations to the use of 
the results in cancer staging and management which will affect outcomes and 
survival. It is clear from the above findings that properly designed studies calculating 
FN correctly and thereby providing accurate values for sensitivity and NPV are 
required to resolve this issue.  
Some newer methods of evaluating metastatic cervical LN like dual-energy spectral 
CT and USS guided FNA thyroglobulin washout are still in their early phases and not 
well established (Liu, Ouyang et al. 2014; Jun, Kim et al. 2015). 
The role of sentinel lymph node (SLN) biopsy in PTC has been investigated and 
debated for a long time. The aim of this is to identify cervical LN metastasis without 
performing a formal LN dissection thus in theory avoiding unnecessary operations.  It 
relies on the progression of metastases in an orderly fashion from the primary organ 
to the sentinel LN or groups of LN’s. Several methods have been used in the 
detection of SLN in PTC namely methylene blue, radio-isotope and combination  of 
techniques(Balasubramanian and Harrison 2011). This method has not gained 
popularity for a variety of reasons. Dye spillage during injection causes problems 
with identification of SLN in addition to causing difficulty in defining other groups of 
LN. Lymphatic disruption during dissection and blockage of the lymph channels with 
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tumour can lead to non-visualisation of the SLN (Abdalla 2006; Peparini, Maturo et 
al. 2006). False identification of SLN for stained parathyroids can lead to excision of 
these glands (Lee, Choi et al. 2009). Rigorous studies are needed to establish this 
technique to be used in management of PTC. 
 
5.7 Limitations  
1. The review was not registered in accordance with PRISMA guidelines on databases 
such as PROSPERO.  

































Chapter 6  



















6.1 Aims and Objectives 
1. To compare the outcomes between prophylactic lateral cervical LN dissection 
versus no lateral LND.  
2. To determine the extent of lateral cervical LN metastasis after prophylactic lateral 
LN Dissection.  
 
6.2 Methods and Methodology 
Study period was 9 years from 2004-2012.  
We conducted a retrospective study at two large hospitals in London namely  
• King’s College Hospital (KCH) 
• Guy’s and St. Thomas’ Hospital (GSTT) 
A comprehensive list of all patients treated for PTC was obtained in liaison with the 
histopathology department from the above centres. All patients had undergone 
surgery for PTC. All available information and data was collected from individual 
patient case notes, Electronic Patient Records (EPR), radiology reporting system, 
histopathology reporting system, letters from Thyroid Multidisciplinary team (MDT) 
meetings and nuclear medicine department. Histological classification was done 
according to World Health Organisation (WHO) classification of thyroid tumours 
(Hedinger 1989). Staging was done according to TNM classification (7th Edition) of 
thyroid cancer (Sobin L 2002). The data was collected in accordance with the 
National and regional guidelines of these trusts. Ethical approval was sought and was 
deemed not necessary by the ethics committee. All data was anonymised and stored 
in a password protected hard drive and on an encrypted USB.  
 
The data collected included: 
• Demographics 
• Pre-operative imaging  
• Type of surgical procedure i.e Lobectomy, TT, LN Dissection 
• Type of Lymph Node dissection whether prophylactic or therapeutic  
• Extent of cervical LN dissection 
• Prevalence of LN metastases in central and lateral compartment 
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• Recurrence and methods used for its detection 
• Follow-up data was collected to the last clinic letter 
• Outcomes of surgery relating to recurrence and survival. 
 
Management regimes at the two centres 
The surgical management of thyroid cancer at the two centres differed mainly for 
tumours T3 and above. Patients from King’s College Hospital with tumours pT3 and 
above, were likely to have prophylactic MRND although this was found not to be 
consistent for all patients. At the other centre, namely GSTT similar cohort of 
patients were likely to have lateral cervical LN dissection only if metastatic LN were 
detected pre-operatively on imaging or clinical examination.  
It must be emphasised that it is not possible to discuss here, the individual scenarios 
that might have transpired or influenced the surgical management of individual 
cases discussed and decided in the multi-disciplinary meetings.  
For our analysis, we divided the patients into two Cohorts as follows- 
Cohort A (Prophylactic Lateral Cervical LND) - In this group the surgical approach 
was prophylactic MRND. These patients had total thyroidectomy and Modified 
Radical Neck Dissection along with central LN dissection. This group included only 
those patients who did NOT have any suspicious or metastatic lateral LN on clinical 
examination, imaging and intra-operatively. 
Prophylactic MRND was defined as type III MRND with removal of cervical LN from 
levels II to V irrespective of pre-operative/intra-operative findings or pre-operative 
imaging with preservation of the spinal accessory nerve, internal jugular vein and 
sternocleidomastoid muscle (Sakorafas, Sampanis et al. 2010). Neck levels were 
defined according to the consensus statement on classification of cervical LN as 
defined by Robbins et. al (Robbins, Shaha et al. 2008). The surgeon removed all 
upper, middle, lower jugular LN including those from the posterior triangle of the 
neck corresponding to levels II to V. 
Cohort B (Central Cervical LND)-This group of patients had total thyroidectomy and 
therapeutic central cervical LND. None of these patients had suspicious or confirmed 
lateral LN metastasis on pre-operative imaging or clinical examination.  
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This operative procedure involved dissection of the level VI compartment to remove 
pre-tracheal, para-tracheal nodes, pre-cricoid (Delphian) and the peri-thyroidal 
nodes along with fatty tissue and fascia. 
 
Recurrence  
Cervical LN or loco-regional recurrence was defined as evidence of LN metastases at 
least six months after completion of initial treatment (surgery+/-RAI treatment). 
Recurrence was suspected by clinical or ultrasound examination and confirmed by 
aspiration cytology, resection, high levels of Tg or by imaging studies, such as post I 
I31 treatment whole body scan or Positron Emission Tomography (PET). Histological 
confirmation of nodal metastases was confirmed in all cases after surgery. 
In case of suspicious or metastatic cervical LN detected prior to this period of six 
months, this was considered as ‘persistence of disease.’ 
 
6.3 Statistical Methods 
All statistical analysis was performed using the software SPSS version 21 (SPSS Inc., 
Chicago, IL). We calculated mean, median, standard deviation and the range for the 
descriptive variables. For uni-variate analysis of the risk factors, chi-square values 
and Pearson’s correlation coefficient (p-values) were calculated for comparison 
between the two groups. P < 0·05 was considered statistically significant. 
To calculate the recurrence free survival, we used Kaplan-Meier survival curves. 
 
6.4 Results 
There were 224 patients in total who had surgery for thyroid cancer in the two 
centres over a 9-year period. There were 51 males and 173 female patients. 74 
patients belonged to KCH and 150 were treated at GSTT. The demographics and 
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†-King’s College Hospital 
‡-Guy’s and St. Thomas’ Hospital 
 
There were total of 13 recurrences, 3 in the KCH and 10 in the GSTT cohort. All 3 
recurrences in the KCH cohort were loco-regional. There were no deaths in this 
cohort. Out the 10 recurrences in the GSTT cohort, 2 patients had both loco-regional 
and distant recurrence; 6 patients had locoregional recurrence only with no distant 
recurrence; 2 had distant recurrence with no locoregional recurrence.  
There were 3 deaths in this cohort; all three patients had advanced disease (T4N1b) 
on presentation and had undergone LND. All developed recurrence and had RAI 
treatment for the same.  
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The flow of patients and the outcomes for all patients from KCH are as shown in 
Figure 6.1. The available TNM staging of all patients as per the surgical procedure 
performed is shown in Table 6.2.  
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Similarly, the flow of patients and the outcomes for all patients from Guy’s and St. 



































































































‡-Includes Ipsilateral and Bilateral CLND 
±-Includes Ipsilateral, Bilateral LLND and selective compartmental LND 
 
The available TNM staging of all patients from GSTT as per the surgical procedure 

















































































































Results of Analysis of the two Cohorts 
Figure 6.3 shows the flow of patients and the process of inclusion in the two cohorts. 
 
 
Total of 44 patients fulfilled the above inclusion and exclusion criteria and hence 
were included in the analysis. 31 patients had TT and central LND whilst 13 patients 
had TT+CLND prophylactic lateral LND. There were 10 males and 34 female patients 
with a mean age of 43.3 years. The median follow-up period was 28 months (Range: 
1-96 months). Of the 13 patients who had prophylactic lateral LND, 7 (53.8%) were 
found to have positive LN on histology. Among the central LND group, out of 31 
patients 9 (29%) were found to have positive LN. Uni-variate analyses between 
gender, tumour size and focality did not show any significant difference among the 
two groups (Table 6.4). Patients undergoing central LND were older and there was a 
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n: number of patients with available data  
n.s: not statistically significant 
LN:  lymph nodes  
 
 
Table 6.5 Results of Central Lymph Nodes Dissection-part of LLND 
from the KCH Cohort 
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n- Number of patients with available data  
LN-lymph nodes  
 
There were no recurrences in the prophylactic group whilst there was one 
recurrence in the CLND group. Kaplan-Meir analysis showed that recurrence free 


























Results of Radio-iodine treatment 
The mean dose of Radio-iodine (RAI) in the prophylactic lateral LND and central LND 
groups was 5.0 GBq (SD±2.8) and 6.0 GBq (SD±5.5) respectively. This was not 
statistically significant. The mean number of RAI doses in the prophylactic lateral LND 
and central LND groups was 1.2 (SD±0.7) and 1.2 (SD±1.0) respectively. The 
difference also was not statistically significant (Table 6.6). 
 





































































      n-number of patients with available data 
      n.s: not statistically significant  
  
 6.5 Discussion      
For decades, there has been considerable controversy regarding the type of surgical    
       approach and the extent of lateral cervical lymph node dissection in PTC. This debate   
       is compounded by lack of data on long term outcomes and survival.  
In this study, more than half of patients who underwent pLLND had metastatic 
lateral LN. We have also shown from previous systematic review that lateral cervical 
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LN metastases were found in nearly 50% of patients when prophylactic LND was 
performed (Mulla, Knoefel et al. 2012). Other studies have shown that more than 
half of PTC patients with metastatic central LN also had metastatic lateral LN (Hartl, 
Leboulleux et al. 2012).  
There was only one recurrence in central LND cohort and no recurrences in the 
pLLND group. Kaplan Meir analysis showed ‘recurrence free survival’ between the 
two cohorts not to be significant.  
We could not perform any meaningful analysis of known risk factors for recurrence 
of disease as there was only one recurrence in the two cohorts combined. We also 
could not perform five or 10-year recurrence free survival because of very small of 
patients in the data with long enough follow-up period for any meaningful statistical 
analysis. There were no deaths in either cohort; hence overall ‘Overall Survival’ was 
100%. 
The pros and cons of prophylactic lateral LND have been discussed in the preceding 
chapters. Although lateral LN metastasis appears to be quite common, their 
significance in relation to long-term outcomes is not very clear. The main reason for 
this is the lack of long term follow-up data required to obtain any meaningful results. 
In an ideal scenario, data from randomised controlled trials with long term follow-up 
would be required to assess long term outcomes. For a slow growing tumour such as 
PTC, it is difficult to organise RCT as this would need long term follow-up to achieve 
any meaningful statistical significance (Shaha 2004). The feasibility of conducting a 
prospective randomized controlled trial comparing prophylactic central node 
dissection versus no prophylactic central node dissection for cN0 PTC has been 
analyzed by a multidisciplinary subcommittee of the ATA Surgical Affairs Committee 
(Carling, Carty et al. 2012). They concluded that ‘given the low rates of both newly 
identified structural disease, prohibitively large sample sizes would be required for 
sufficient statistical power to demonstrate significant differences in outcomes’ 
(Carling, Carty et al. 2012). ‘Thus, a prospective RCT of prophylactic central lymph 
node dissection in cN0 PTC was not readily feasible’ (Carling, Carty et al. 2012). 
Out of the studies providing long term data, some have shown that cervical LN 
metastases were related to a higher recurrence rate, but did not adversely influence 
survival (Hay, Grant et al. 1992). Other authors have documented that the presence 
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of lymph node metastases adversely influenced disease free and overall survival 
(Scheumann, Gimm et al. 1994; Ito, Higashiyama et al. 2007). There is evidence in 
literature from large studies and reviews confirming that lateral cervical involvement 
(II-V) has poor survival and an increased risk of death from PTC (Smith, Sessions et al. 
2012; Eskander, Merdad et al. 2013). In our study the because of small number of 
patients and short follow-up period, (Median=28 months) it was not possible to draw 
any meaningful long term conclusions. 
There are also studies from large registries like SEER (Surveillance, Epidemiology, and 
End Results) database from United States of America. One such study demonstrated 
lymph node status to be an independent predictor of survival in PTC patients 
>45years of age but did not affect survival in <45 years (Zaydfudim, Feurer et al. 
2008). A similar recent SEER based study with nearly 26,000 PTC patients 
demonstrated a significant association between lymph node involvement and 
cumulative incidence of death from thyroid cancer (P<0.001). There are other 
studies which show that cervical LN metastases were related to a higher recurrence 
rate, but did not adversely influence survival (Hay, Grant et al. 1992). Others have 
reported that the presence of lymph node metastases adversely influenced survival 
(Scheumann, Gimm et al. 1994). A study by Ito Y and colleagues demonstrated that 
clinically identified lymph node metastases are associated with a worse disease free 
and overall survival (Noguchi, Murakami et al. 1998; Ito and Miyauchi 2007). A 
recent study of a large series of more than 11,000 PTC patients concluded that 
patients aged >45 years with lateral/mediastinal cervical involvement have an 
increased risk of death from PTC (Smith, Sessions et al. 2012). These studies however 
do not provide a comparison between prophylactic and therapeutic LND in PTC. 
There are few studies comparing prophylactic to therapeutic LND with regards to 
long term outcomes. One such is a study conducted by Barczynski and colleagues 
(Barczynski, Konturek et al. 2013) who looked at central LN only. This was a 
retrospective cohort study of patients who underwent total thyroidectomy (TT) with 
bilateral prophylactic CND (n=358) compared with patients who had TT without CND 
(n=282). The 10-year disease-specific survival rate for patients who had TT without 
CND was 92·5% compared with 98% in patients with CND (P = 0·034), and the loco-
regional control rate was 87·6 and 94·5% respectively (P = 0·003). They concluded 
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that bilateral pCND, improved both 10-year disease-specific survival and loco-
regional control, without increasing the risk of permanent morbidity.    
A recent study with cohort similar to our analysis was performed by Lim YC and 
colleagues (Lim, Liu et al. 2016). They studied all patients who underwent TT+CLND 
without any clinical evidence of lateral LN involvement; the study found lateral LN 
recurrence in 4.5% of patients. Tumour size >1 cm and central LN metastasis were 
independent predictors of lateral LN recurrence. 
 
6.6 Limitations of Cohort Study 
-As this was a retrospective study, it had significant deficiencies. 
-Collection of data was reliant on the availability of complete histology reports, 
accurate imaging reports, operative notes and follow-up data. This was found to be 
significantly deficient on all the above parameters in-spite of our best efforts to 
gather all the data. 
-There was a lot of variability in terms of information provided on the histology 
reports. This meant that all the required information could not be collected 
consistently and there was a lot of missing data.  
-Some of the imaging reports were also not available. This again meant missing data 
which could not be collected. 
-The median follow-up period for the prophylactic groups was less than 2 years. This 













6.7 Summary of Conclusions 
 
• Prophylactic lymph node dissection yielded metastatic central and lateral 
lymph nodes in about half of all patients with Papillary Thyroid Carcinoma. 
Frequency of cervical LN metastasis increases proportionately with the stage of 
disease. 
• Imaging modalities currently utilised for detection of both central and lateral 
metastatic cervical LN namely US and CT have low sensitivities and hence not 
entirely reliable in detecting metastatic cervical LN. 
• There was no difference in the clinical outcomes between prophylactic lateral 
LND versus no lateral LND in our study. This must be viewed within limitations 
of the study with small numbers involved and the short follow-up.  
• A randomised controlled trial comparing prophylactic versus therapeutic LND 
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